Daniel L. Gillen, Ph.D.
Chancellor's Professor and Chair of Statistics
Chancellor's Professor of Epidemiology & Biostatistics and Population Health & Disease Prevention
University of California, Irvine
2226 Bren Hall, Irvine, CA 92697-1250
Email: dgillen@uci.edu   Web: https://dgillen.ics.uci.edu
Phone: 949.824.9862   Fax: 949.824.9863

Research Interests

Survival analysis, longitudinal data analysis, clinical trials, sequential testing, epidemiologic methods

Education

1998-2003, Ph.D., Biostatistics, University of Washington, Seattle, WA.

1998-2001, M.S., Biostatistics, University of Washington, Seattle, WA.

1995-97, B.S., Mathematics, Cal Poly State University, San Luis Obispo, CA.

Positions

Academic Appointments

2022 - present, Chancellor's Professor and Chair, Department of Statistics, University of California, Irvine

2016 - present, Chair, Department of Statistics, University of California, Irvine

2014 - present, Professor, Department of Statistics, University of California, Irvine

2014 - present, Professor, Department of Epidemiology & Biostatistics, University of California, Irvine

2014 - present, Professor, Department of Population Health & Disease Prevention, University of California, Irvine

2008 - 2014, Associate Professor, Department of Statistics, University of California, Irvine

2012 - 2014, Associate Professor, Program in Public Health, University of California, Irvine

2008 - 2014, Associate Professor, Department of Epidemiology, University of California, Irvine

2005 - 2008, Assistant Professor, Department of Epidemiology, University of California, Irvine

2004 - 2008, Assistant Professor, Department of Statistics, University of California, Irvine

2003 - 2004, Assistant Professor, Department of Health Studies, University of Chicago

Research Centers

2008 - present, Director of Data and Statistics, Alzheimer Disease Research Center, UC Irvine, CA.

2010 - 2016, Director of Statistics, Chao Family Comprehensive Cancer Center, UC Irvine, CA.

Academic Awards and Scholarships

Fellow, American Association for the Advancement of Science (2024)

Dean's Award for Research, School of Information and Computer Science, University of California, Irvine (2023).

Chancellor's Professor, University of California, Irvine (2022).

Dean's Award for Graduate Mentoring, School of Information and Computer Science, University of California, Irvine (2019).

Fellow, American Statistical Association (2016).

Mid-Career Award for Excellence in Research, School of Information and Computer Science, University of California, Irvine (2016).

Clinical Research, Education, and Awareness Award, Chao Cancer Center, University of California, Irvine (2013).

Dean's Award for Service, School of Information and Computer Science, University of California, Irvine (2013).

Excellence in Mentoring Award, Institute for Clinical and Translational Sciences, University of California, Irvine (2011).

CORCL Travel Award, University of California, Irvine (2005, 2006, 2014. 2018, 2019).

NIH Travel Award, International Biometrics Conference (Cairnes, AUS; 2004).

NIH Travel Award, ENAR Young Investigators Meeting (Pittsburgh, PA; 2004).

WNAR Student Paper Competition, "Information growth in a family of weighted logrank statistics under interim analyses", 1st place written paper, 1st place oral presentation (2003).

Outstanding Student in Biostatistics Award, School of Public Health, University of Washington (2003).

Donovan J. Thompson Award for excellence in applied and theoretical Biostatistics, Dept. of Biostatistics, University of Washington (2000).

NIH Cancer-Epidemiology-Biostatistics Training Grant (1999 - 2003).

Professional Memberships

American Association for the Advancement of Science (2019-present)

American Statistical Association (2003-present)

International Biometric Society (2002-present)

American Society of Nephrology (2004-present)

PhD Students

Supervised Doctoral Students (Sole primary advsior unless noted)

1. Adam Boyd, Senior Director of Biostatistics, Array Biopharma Inc, Denver, CO (completed 2009; co-advised with John Kittelson, UC Denver); Dissertation Title: "Censoring-Robust Treatment Effect Estimation in Clinical Trials with Time-to-Event Outcomes"

2. Sean Brummel, Research Associate, Department of Biostatistics, Harvard University (completed 2010); Dissertation Title: "On Monitoring Group Sequential Trials in the Presence of Non-Linear Information Growth and Surrogate Information"

3. Vinh Nguyen, Head, Education Analytics, Irvine Valley College (completed 2011); Dissertation Title: "Robust Inference and Group Sequential Methods in Discrete Hazards Models"

4. Steven Kim, Assistant Professor, Department of Mathematics and Statistics, CSU Monterey Bay (completed 2015) Dissertation Title: "Bayesian Dose-Response Modeling in Sparse Data"

5. Sevan Gullesserian, Lecturer, Department of Statistics, University of California, Irvine, (completed 2016) Dissertation Title: "Statistical methods for the analysis of unbalanced case-crossover designs"

6. Lu Bai, Senior Biostatistician, LeanTaas, San Francisco, CA (completed 2016) Dissertation Title: "Statistical Methods for Quantifying Spatial Effects on Disease Incidence Using Individual-Level Data"

7. Sepehr Akhavan, Data Scientist, Facebook (completed 2016) Dissertation Title: "Joint Longitudinal Survival Models Using Gaussian Process Priors"

8. Andrew Holbrook, Assistant Professor of Biostatistics, UCLA (completed 2018; co-advised with Babak Shahbaba)

9. Maricela Cruz, Assistant Research Associate, Kaiser, Seattle WA (completed 2019) NSF GRFP Recipient; Eugene Cota-Robles Fellow; Dissertation Title: "Interrupted Time Series Models for Assessing Complex Health Care Interventions")

10. Lars Hertel, Data Scientist, Linkedin (completed 2020; co-advised with Pierre Baldi)

11. Yannan Tang, Senior Statistician, Genentech, San Francisco, CA (completed 2020)

12. Mary Ryan, Assistant Professor of Biostatistics, University of Wisconsin-Madison (completed 2021); UCI Public Health Impact Fellow; NIH Training Grant Recipient

13. Olivia Bernstein, Mathematical Statistician, FDA (completed 2022); NSF GRFP Recipient; ARCS Fellow

14. Zhuoran Zhang, Senior Biostatistician, Merck (completed 2023)

15. Navneet Hakhu, Post-doc Harvard University (completed 2024); NIH Training Grant Recipient; NIH F31 Fellow

16. Cangao Chu, Department of Statistics, (completed 2024); NIH Training Grant Recipient

17. Kyle Conniff, Post-doc University of Wisconsin-Madison; (completed 2024); NSF GRFP Recipient, NIH Diversity Supplement Recipient

18. Roy Zawadzki, Equity Research Biostatistician, Jeffries (completed 2025); NIH Training Grant Recipient

19. Adam Birnbaum, Department of Statistics, UC Irvine (2021 to present; Advanced to candidacy in 2024); NSF GRFP Recipient

20. Thuy Lu, Senior Biostatistician, Arrowhead Pharmaceuticals (completed 2025); UCI MIND Training Grant Recipient

21. Mikaela Nishida, Department of Statistics, UC Irvine (2021 to present); NIH Diversity Supplement Recipient

22. Yiren (Sam) Xu, Department of Statistics, UC Irvine (2022 to present)

23. Christina Magana-Ramirez, Department of Statistics, UC Irvine (2022 to present); NSF GRFP Recipient

24. Sarah Schlund, Department of Statistics, UC Irvine (2023 to present)

25. Sean Leader, Department of Statistics, UC Irvine (2024 to present)

Doctoral Candidacy Committees

1. Rene Bravo, Chemistry, Outside Member, 2006

2. Michael Yi, Mathematical and Behavioral Sciences, Outside Member, 2007

3. Zachary Nye, Business, Outside Member, 2008

4. Mark Washburn, Business, Outside Member, 2008

5. Matthew Zeigenfuse, Mathematical and Behavioral Sciences, Outside Member, 2009

6. Jie Shen, Statistics, Member, 2010

7. Clifford Anderson-Bergman, Statistics, Member, 2011

8. Hyeong Moo Shin, Public Health, Member, 2011

9. Yan He, Statistics, Member, 2011; Reading Committee, 2014

10. Tolga Bahattin, Mathematical and Behavioral Sciences, Outside Member, 2012

11. Shiwei Lan, Statistics, Member, 2012

12. Luis Sotoort, Biomedical Engineering, Outside Member, 2012

13. Thomas Debeauvais, Informatics, Member, 2012

14. Kevin Heins, Statistics, Member 2012; Reading Committee, 2014

15. Sharine Witkopp, Epidemiology, Member 2012; Reading Committee, 2014

16. David Stenning, Statistics, Member, 2012

17. Brian Vegetabile, Statistics, Member, 2015

18. Elizabeth Ward, Statistics, Member, 2015

19. Michael Guggisberg, Economics, Member, 2015

20. Dustin Pluta, Statistics, Member, 2017

21. Wendy Rummerfeld, Statistics, Member, 2019

22. Marina Ritchie, Neurobiology & Behavior, Member, 2021

23. Yue Wang, Statistics, Member, 2022

24. Bingqing Hu, Statistics, Member, 2023

Post-Doctoral Supervision

Christian Salazar, Co-Mentored with Josh Grill, UCI MIND, 2019-2021

Jennifer Koontz, Post-Doc supported by the Brain Aging Training Grant (PI: Cotman) and the UCI Alzheimer's Disease Research Center, 2010-2012

Research (Google Scholar h-index: 64; i10-index:143, 21,845 total citations as of 03-Apr-2023)

Published Work (* indicates PhD student)

1. Stehman-Breen C., **Gillen D.**, and Gipson D., "Prescription of hormone replacement therapy in postmenopausal women with renal failure." *Kidney International*, Vol. 56 (1999), pp. 2243-7.

2. Stehman-Breen C., Sherrard D., **Gillen D.**, and Caps M., "Determinants of type and timing of initial permanent hemodialysis vascular access." *Kidney International*, Vol. 57 (2000), pp. 639-45.

3. Alem A., Sherrard D., **Gillen D.**, Weiss N., Beresford S., Heckebert S., Wong C., and Stehman-Breen C., "Increased risk of hip fracture among patients with end-stage renal disease." *Kidney International*, Vol. 58 (2000), pp. 396-9.

4. Wong C., Gipson D., **Gillen D.**, Emerson S., Koepsell T., Sherrard D., Watkins S., and Stehman-Breen C., "Anthropometric measures and risk of death in children with end-stage renal disease." *American Journal of Kidney Diseases*, Vol. 36, No. 4 (2000), pp. 811-9.

5. Stehman-Breen, C., Sherrard, D., Alem, A., **Gillen, D.**, Heckebert, S., Wong, C., Ball, A., and Weiss, N., "Risk factors for hip fracture among patients with end-stage renal disease." *Kidney International*, Vol. 58 (2000), pp. 2200-5.

6. Gibson K., Caps M., **Gillen D.**, Bergelin R., Primozich J., and Strandness D., "Identification of factors predictive of lower extremity vein graft thrombosis." *Journal of Vascular Surgery*, Vol. 33 (2001), pp. 24-31.

7. Gibson K., Caps M., Kohler T., Hatsukami T., **Gillen D.**, Aldassy M., Sherrard D., and Stehman-Breen C., "Assessment of a policy to reduce placement of prosthetic hemodialysis access." *Kidney International*, Vol. 59 (2001), pp. 2335-45.

8. Mazhar A., Johnson R., **Gillen D.**, Stivelman J., Ryan M., Davis C., and Stehman-Breen C., "Risk factors and mortality associated with calciphylaxis in end-stage renal disease." *Kidney International*, Vol. 60 (2001), pp. 324-32.

9. Gibson, K., **Gillen, D.**, Caps M., Kohler T., Sherrard D., and Stehman-Breen C., "Vascular access survival and incidence of revisions: A comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study." *Journal of Vascular Surgery*, Vol. 34 (2001), pp. 694-700.

10. Seliger, S., Weiss, N., **Gillen, D.**, Kestenbaum, B., Ball, A., Sherrard, D., and Stehman-Breen, C., "HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients." *Kidney International*, Vol. 47 (2002), pp. 384-7.

11. Wong C., Hingorani S., **Gillen D.**, Sherrard D., Watkins S., Brandt J., Ball A., and Stehman-Breen C., "Hypoalbuminemia and risk of death in pediatric patients with end-stage renal disease." *Kidney International*, Vol. 61 (2002), pp. 630-7.

12. Fung F., Sherrard D., **Gillen D.**, Wong C., Kestenbaum B., Seliger S., Ball A., and Stehman-Breen C., "Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients." *American Journal of Kidney Diseases*, Vol. 40 (2002), pp. 307-14.

13. Kestenbaum B., **Gillen D.**, Sherrard D., Seliger S., Ball A., and Stehman-Breen C., "Calcium channel blocker use and mortality among patients with end-stage renal disease." *Kidney International*, Vol. 61 (2002), pp. 2157-64.

14. Ball A., **Gillen D.**, Sherrard D., Weiss N., Emerson S., Seliger S., Kestenbaum B., and Stehman-Breen, C., "The risk of hip fracture among dialysis and renal transplant recipients." *JAMA*, Vol. 288 (2002), pp. 3014-8.

15. Seliger S., **Gillen D.**, Longstreth W. Jr, Kestenbaum B., and Stehman-Breen C., "Elevated risk of stroke among patients with end-stage renal disease." *Kidney International*, Vol. 64 (2003), pp. 603-9.

16. Stehman-Breen C., **Gillen D.**, Steffes M., Jacobs D., Lewis C., Kiefe C., and Siscovick D., "Racial and gender differences in early onset renal disease among young adults - the Coronary Artery Risk Development in Young Adults (CARDIA) Study." *Journal of the American Society of Nephrology*, Vol. 14, No. 9 (2003), pp. 2352-7.

17. Wasse H., **Gillen D.**, Ball A., Kestenbaum B., Seliger S., Sherrard D., and Stehman-Breen C., "Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients." *Kidney International*, Vol. 64 (2003), pp. 1455-61.

18. Kestenbaum B., Seliger S., Easterling T., **Gillen D.**, Critchlow C., Stehman-Breen C., Schwartz S., "Cardiovascular and thromboembolic events following hypertensive pregnancy." *American Journal of Kidney Diseases*, Vol. 42 (2003), pp. 982-9.

19. Seliger S., **Gillen D.**, Tirschwell D., Wasse H., Kestenbaum B., Stehman-Breen C., "Risk Factors for incident stroke among patients with end-stage renal disease." *Journal of the American Society of Nephrology*, Vol. 14 (2003), pp. 2623-31.

20. Kestenbaum B., Seliger S., **Gillen D.**, Wasse H., Young B., Sherrard D., Weiss N., Stehman-Breen C., "Parathyroidectomy rates among United States dialysis patients: 1990-1999." *Kidney International*, Vol. 65 (2004), pp. 282-8.

21. Seliger S., Siscovick D., Stehman-Breen C., **Gillen D.**, Fitzpatrick A., Bleyer A., Kuller L.., "Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study." *Journal of the American Society of Nephrology*, Vol. 15, No. 7 (2004), pp. 1904-11.

22. Jani A., Al-Qamari A., Sapra B., Krauz L., Awan A., Kocherginsky M., **Gillen D.**, "Analysis of prostate-specific antigen rebound interval in patients with prostate cancer receiving hormonal therapy and external-beam radiation therapy." *Clinical Prostate Cancer*, Vol. 3, No. 1 (2004), pp. 43-8.

23. Mittalhenkle A., **Gillen D.**, Stehman-Breen C., "Increased risk of mortality associated with hip fracture in the dialysis population." *American Journal of Kidney Diseases*, Vol. 44 (2004), pp. 672-9.

24. Kestenbaum B., Andress D., Schwartz S., **Gillen D.**, Seliger S., Jadav P., Sherrard D., Stehman-Breen C., "Survival following parathyroidectomy among United States dialysis Patients." *Kidney International*, Vol. 66 (2004), pp. 2010-6.

25. **Gillen D.** and Emerson S., "Information growth in a family of weighted logrank statistics under interim analyses" *Sequential Analysis*, Vol. 24 (2005), pp. 1-22.

26. **Gillen D.** and Emerson S., "A note on P-values under group sequential testing and nonproportional hazards" *Biometrics*, Vol. 61 (2005), pp. 546-51.

27. Williams J., Javaid B., Kadambi P., **Gillen D.**, Harland R., Thistlewaite J., Garfinkel M., Foster P., Atwood W., Millis J., Meehan S., Josephson M., "Leflunomide for polyomavirus type BK nephropathy" *New England Journal of Medicine*, Vol. 352, pp. 1157-8.

28. Vokes T., **Gillen D.**, Lovett J., Favus M., "Comparison of T-scores from different skeletal sites in differentiating postmenopausal women with and without prevalent vertebral fractures" *Journal of Clinical Densitometry*, Vol. 8 (2005), pp. 206-15.

29. **Gillen D.**, Worcester E., and Coe F., "Decreased renal function among adults with a history of nephrolithiasis: A study of NHANES III" *Kidney International*, Vol. 67 (2005), pp. 685-90.

30. Santry H., **Gillen D.**, and Lauderdale D., "Trends in bariatric surgical procedures" *JAMA*, Vol. 294 (2005), pp. 1909-17.

31. Seliger S., Longstreth W., Katz R., Manolio T., Fried L., Shlipak M., Stehman-Breen C., Newman A., Sarnak M., **Gillen D.**, Bleyer A., Siscovick D., "Cystatin C and subclinical brain infarction" *Journal of the American Society of Nephrology*, Vol. 16, No. 12 (2005), pp. 3721-7.

32. Fried L., Katz R., Sarnak M., Shlipak M., Chaves P., Jenny N., Stehman-Breen C., **Gillen D.**, Bleyer A., Hirsch C., Siscovick D., Newman AB., "Kidney function as a predictor of noncardiovascular mortality" *Journal of the American Society of Nephrology*, Vol. 16, No. 12 (2005), pp. 3728-35.

33. **Gillen D.**, Coe F., and Worcester E., "Neprholithiasis and increased blood pressure among females with increased BMI" *American Journal of Kidney Diseases*, Vol. 46 (2005), pp. 263-9.

34. Smith J., Rudser K., **Gillen D.**, Kestenbaum B., Seliger S., Weiss N., McDonald R., Davis C., Stehmen-Breen C., "Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System", *Transplantation*, Vol. 81, No. 2 (2006), pp. 175-80.

35. Josephson M., **Gillen D.**, Javaid B., Kadambi P., Meehan S., Foster P., Harland R., Thistlethwaite R., Garfinkel M., Atwood W., Jordan J., Sadhu M., Millis M., Williams J., "Treatment of renal allograft polyoma BK virus infection with leflunomide", *Transplantation*, Vol. 81, No. 5 (2006), pp. 704-10.

36. Delfino R., Staimer N., **Gillen D.**, Tjoa T., Sioutas C., Fung K., George S., Kleinman M.. "Personal and ambient air pollution is associated with increased exhaled NO in children with asthma" *Environ Health Perspect*, Vol. 114, No. 11 (2006), pp. 1736-43.

37. Vokes T., **Gillen D.**, Pham A., Lovett J., "Risk factors for prevalent vertebral fractures in black and white female densitometry patients." *Journal of Clinical Densitometry*, Vol. 10 (2007), pp. 1-9.

38. Worcester E., **Gillen D.**, Evan A., Parks J., Wright K., Trumbore L., Nakagawa Y., and Coe F., "Evidence that postprandial reduction of renal calcium reabsorption mediates the hypercalcuria of patients with calcium nephrolithiasis", *American Journal of Physiology - Renal Physiology*, Vol. 292, No. 1 (2007), pp. 66-75.

39. Stankus N., Hammes M., **Gillen D.**, and Worcester E., "African American ESRD patients have a high pre-dialysis prevalence of kidney stones compared to NHANES III", *Urological Research*, Vol. 35, No. 2 (2007), pp. 83-7.

40. Emerson S., Kittelson J., and **Gillen D.**, "Bayesian evaluation of group sequential clinical trial designs", *Statistics In Medicine*, Vol. 26, No. 7 (2007), pp. 1431-49.

41. **Gillen D.** and Emerson S., "Non-transitivity in a class of weighted logrank statistics under nonproportional hazards", *Statistics and Probability Letters*, Vol. 77, No. 2 (2007), pp. 123-130.

42. Emerson S., Kittelson J., and **Gillen D.**, "Frequentist evaluation of group sequential clinical trial designs", *Statistics In Medicine*, Vol. 26, No. 28 (2007), pp. 5047-80.

43. **Gillen D.**, Worcester E., and Coe F., Response to comments on Evidence that postprandial reduction of renal calcium reabsorption mediates the hypercalcuria of patients with calcium nephrolithiasis, *American Journal of Physiology -Renal Physiology*, Vol. 293, No. 6 (2007), pp. 1759.

44. Delfino R., Staimer N., Tjoa T., **Gillen D.**, Kleinman M., Sioutas C., and Cooper D. Personal and ambient air pollution exposures and lung function decrements in children with asthma *Environ Health Perspect*, Vol. 116, No. 4 (2008), pp. 550-8.

45. Mittalhenkle A., Stehman-Breen C., Shlipak M., Fried L., Katz R., Young B., Seliger S., **Gillen D.**, Newman A., Psaty B., and Siscovick D. "Cardiovascular risk factors and incident acute renal failure in older adults: the cardiovascular health study." *Clin J Am Soc Nephrol*, Vol. 3, No. 2 (2008), pp. 450-6.

46. Evan A., Coe F., **Gillen D.**, Lingeman J., Bledsoe S., and Worcester E. "Renal intratubular crystals and hyaluronan staining occur in stone formers with bypass surgery but not with idiopathic calcium oxalate stones." *Anat Rec*, Vol. 291, No. 3 (2008), pp. 325-34.

47. Chen P., Kuraguchi M., Velasquez J., Wang Y., Yang K., Edwards R., **Gillen D.**, Edelmann W., Kucherlapati R., and Lipkin S. "Novel roles for MLH3 deficiency and TLE6-like amplification in DNA mismatch repair-deficient gastrointestinal tumorigenesis and progression." *PLoS Genet* Vol. 4, No. 6 (2008), e1000092.

48. Delfino R., Staimer N., Tjoa T., Polidori A., Arhami M., **Gillen D.**, Kleinman M., Vaziri N., Longhurst J., Zaldivar F., and Sioutas C."Circulating biomarkers of inflammation, antioxidant activity, and platelet activation are associated with primary combustion aerosols in subjects with coronary artery disease." *Environ Health Perspect*, Vol. 116, No. 7 (2008), pp. 898-906.

49. **Gillen D.**, Stehman-Breen C., Smith J., McDonald R., Warady B. Brandt J., and Wong C., "The survival advantage of pediatric recipients of a first kidney transplant among children awaiting kidney transplantation." *American Journal of Transplantation*, Vol. 8, No. 12 (2008), pp. 2600-6.

50. Meyskens F. Jr, McLaren C., Pelot D., Fujikawa-Brooks S., Carpenter P., Hawk E., Kelloff G., Lawson M., Kidao J., McCracken J., Albers C., Ahnen D., Turgeon D., Goldschmid S., Lance P., Hagedorn C., **Gillen D.**, and Gerner E. "Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial", *Cancer Prev Res*, Vol. 1, No. 1 (2008), pp. 32-38.

51. Haneuse S., Rudser K., and **Gillen D.** "The separation of timescales in Bayesian survival modeling of the time-varying effect of a time-dependent exposure.", *Biostatistics*, Vol. 9, No. 3 (2008), pp. 400-10.

52. Schildcrout J., Jenkins C., Ostroff J., **Gillen D.**, Harrell F., and Trost D. "Analysis of longitudinal laboratory data in the presence of common selection mechanisms: a view toward greater emphasis on pre-marketing pharmaceutical safety", *Statistics In Medicine*, Vol. 27, No. 12 (2008), pp. 2248-66.

53. **Gillen D.** and Johnson W., Comment on The Nested Dirichlet Process, *Journal of the American Statistical Association*, Vol. 103, No. 483 (2008), pp. 1155.

54. Delfino R., Brummel S.,* Wu J., Stern H., Ostro B., Lipsett M., Winer A., Street D., Zhang L., Tjoa T., and **Gillen D.** "The relationship of respiratory and cardiovascular hospital admissions to the southern California wildfires of 2003", *Occup Environ Med*, Vol. 66, No. 3 (2009), pp. 189-97.

55. Miller N., **Gillen D.**, Williams J. Jr, Evan A., Bledsoe S., Coe F., Worcester E., Matlaga B., Munch L., and Lingeman J. "A formal test of the hypothesis that idiopathic calcium oxalate stones grow on Randall's plaque", *BJU Int.*, Vol. 103, No. 7 (2009), pp. 966-71.

56. McLaren C., Fujikawa-Brooks S., Chen W., **Gillen D.**, Pelot D., Gerner E., and Meyskens F. Jr., "Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas", *Cancer Prev Res*, Vol. 1, No. 7 (2008), pp. 514-21.

57. Chang J.,* Delfino R., **Gillen D.**, Tjoa T., Nickerson B., and Cooper D. "Repeated respiratory hospital encounters among children with asthma and residential proximity to traffic", *Occup Environ Med*, Vol. 66, No. 2 (2009), pp. 90-8.

58. Delfino R., Chang J.,* Wu J., Ren C., Tjoa T., Nickerson B., Cooper D., and **Gillen D.**, "Repeated hospital encounters for asthma in children and exposure to traffic-related air pollution near the home", *Ann Allergy Asthma Immuno*, Vol. 102, No. 2 (2009), pp. 138-44.

59. Sarsoza F., Saing T., Kayed R., Dahlin R., Dick M., Broadwater-Hollifield C., Mobley S., Lott I., Doran E., **Gillen D.**, Anderson-Bergman C.*, Cribbs D., Glabe C., and Head E. "A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain", *Acta Neuropathol.* Vol. 118, No. 4 (2009), pp. 505-17.

60. Johnson M.*, Edwards R., Ghilardi A., Berrueta V., **Gillen D.**, Frenk C., and Masera O., "Quantification of carbon savings from improved biomass cookstove projects", *Environ Sci Technol*, Vol. 43, No. 7 (2009), pp. 2456-62.

61. Bergsland K., Coe F., **Gillen D.**, and Worcester E., "A test of the hypothesis that collecting duct calcium sensing receptor limits rise of urine calcium molarity in hypercalciuric calcium kidney stone formers", *Am J Physiol Renal Physiol*, Vol. 297, No. 4 (2009), pp. F1017-23.

62. Delfino R., Staimer N., Tjoa T., **Gillen D.**, Polidori A., Arhami M., Kleinman M., Vaziri N., Longhurst J., and Sioutas C. "Air pollution exposures and circulating biomarkers of effect in a susceptible population: clues to potential causal component mixtures and mechanisms." *Environ Health Perspect*, Vol. 117, No. 8 (2009), pp. 1232-8.

63. **Gillen D.**, "A Random Walk Approach for Quantifying Uncertainty in Group Sequential Survival Trials" , *Computational Statistics and Data Analysis*, Vol. 53, No. 3 (2009), pp. 603-620.

64. Neuhausen S., Brummel S.*, Ding Y., Singer C., Pfeiler G., Lynch H., Nathanson K., Rebbeck T., Garber J., Couch F., Weitzel J., Narod S., Ganz P., Daly M., Godwin A., Isaacs C., Olopade O., Tomlinson G., Rubinstein W., Tung N., Blum J., and **Gillen D.** "Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers", *Breast Cancer Res*, Vol. 11, No. 5 (2009), pp. R76.

65. Delfino R., Staimer N., Tjoa T., Arhami M., Polidori A., **Gillen D.**, Kleinman M., Schauer J., and Sioutas C., "Association of biomarkers of systemic inflammation with organic components and source tracers in quasi-ultrafine particles", *Environ Health Perspect*, Vol. 118, No. 6 (2010), pp. 756-62.

66. Vokes T. and **Gillen D.**, "Using clinical risk factors and bone mineral density to determine who among patients undergoing bone densitometry should have vertebral fracture assessment", *Osteoporos Int*, Vol. 21, No. 12 (2010), pp. 2083-91.

67. Delfino R., Tjoa T., **Gillen D.**, Staimer N., Polidori A., Arhami M., Jamner L., Sioutas C., and Longhurst J., "Traffic-related air pollution and blood pressure in elderly subjects with coronary artery disease", *Epidemiology*, Vol. 21, No. 3 (2010), pp. 396-404.

68. Pop V.*, Head E., Hill M., **Gillen D.**, Berchtold N., Muggenburg B., Migalska N., Milgram N., Murphy M., and Cotman C., "Synergistic effects of long-term antioxidant diet and behavioral enrichment on beta-amyloid load and non-amyloidogenic processing in aged canines", *Journal of Neuroscience*, Vol. 30., No. 29 (2010), pp. 9831-9.

69. Delfino R., Staimer N., Tjoa T., Arhami M., Polidori A., **Gillen D.**, George S., Shafer M., Schauer J., and Sioutas C., "Associations of primary and secondary organic aerosols with airway and systemic inflammation in an elderly panel cohort", *Epidemiology*, Vol. 21, No. 6 (2010), pp. 892-902.

70. Astarita G., Jung K., Berchtold N., Nguyen V., **Gillen D.**, Head E., Cotman C., and Piomelli D., "Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease", *PLoS One*, Vol. 5, No. 9 (2010), e12538.

71. Vary, L.*, **Gillen D.**, Randrianjanahary, M., Lowry, P., II, Sakai, A. K., Weller, S. G. "Dioecy, Monoecy, and Their Ecological Correlates in the Littoral Forest of Madagascar", *Biotropica*, 43(5) (2011), 582-90.

72. Delfino R., **Gillen D.**, Tjoa T., Staimer N., Polidori A., Arhami M., Sioutas C., and Longhurst J., "Electrocardiographic ST-segment depression and exposure to traffic-related aerosols in elderly subjects with coronary artery disease", *Environ Health Perspect*, Vol. 119, No. 2 (2011), pp. 196-202.

73. Neuhausen, S., Brummel, S.*, Ding, Y., Steel, L., Nathanson, K., Domchek, S., Rebbeck, T., Singer, C., Pfeiler, G., Lynch, H., Garber, J., Couch, F., Weitzel, J., Godwin, A., Narod, S., Ganz, P., Daly, M., Isaacs, C., Olopade, O., Tomlinson, G., Rubinstein, W., Tung, N., Blum, J., **Gillen D.** "Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers", *Cancer Epidemiol Biomarkers Prev*, 20(8) (2011), 1690-702.

74. Lott, I. T., Doran, E., Nguyen, V.*, Tournay, A., Head, E., **Gillen D.** "Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation", *Am J Med Genet A*, 155A(8) (2011), 1939-48.

75. Haneuse S., Schildcrout J., and **Gillen D.** "A two-stage strategy to accommodate general patterns of confounding in the design of observational studies", *Biostatistics*, Vol. 13, No. 2 (2012), pp. 274-88.

76. **Gillen D.** and Emerson S., "Designing, Monitoring, and Analyzing Group Sequential Clinical Trials Using the RCTdesign Package for R", *Proceedings of the 4th Seattle Symposium on Biostatistics* (Peer-Reviewed), Editors: Thomas R. Fleming and Bruce S. Weir, Springer, New York (2013) pp. 177-208.

77. Ding Y. et al., "A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers", *Cancer Epidemiol Biomarkers Prev*, 21(8) (2012), 1362-1370.

78. Lott I, Doran E, Nguyen V*, Tournay A, Movsesyan N, and **Gillen D.**, "Down syndrome and dementia: seizures and cognitive decline", *J Alzheimers Dis.*, 29(1) (2012), 177-85.

79. Boyd A*., Kittelson J., and **Gillen D.** "Estimation of treatment effect under nonproportional hazards and conditionally independent censoring", *Statistics in Medicine*, Vol. 31, No. 28 (2012), pp. 3504-15.

80. Nguyen V.* and **Gillen D.** "Robust Inference in Semiparametric Discrete Hazard Models for Randomized Clinical Trials", *Lifetime Data Analysis*, Vol. 18, No. 4 (2012), pp. 446-69.

81. Yu Z., **Gillen D.**, Li C., and Demetriou M. "Incorporating Parental Information Into Family-Based Association Tests", *Biostatistics*, Vol. 14, No. 3 (2013), pp. 556-72. PMID: 23266418

82. Berchtold NC, Coleman PD, Cribbs DH, Rogers J, **Gillen D.**, Cotman CW. "Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease", *Neurobiol Aging* Vol. 34, No.6 (2013), pp. 1653-61. PMID: 23273601

83. Delfino RJ, Staimer N, Tjoa T, **Gillen D.**, Schauer JJ, Shafer MM. "Airway inflammation and oxidative potential of air pollutant particles in a pediatric asthma panel", *J Expo Sci Environ Epidemiol*, Vol. 23, No. 5 (2013) pp. 466-73. PMID: 23673461

84. Wittkopp S*, Staimer N, Tjoa T, **Gillen D**, Daher N, Shafer M, Schauer JJ, Sioutas C, Delfino RJ., "Mitochondrial Genetic Background Modifies the Relationship between Traffic-Related Air Pollution Exposure and Systemic Biomarkers of Inflammation", *PLoS One.* Vol. 8, No. 5 (2013), e64444. PMID: 23717615

85. Brummel S.* and **Gillen D.** "On the use of local assessments for monitoring centrally reviewed endpoints with missing data in clinical trials", *Open Journal of Statistics*, Vol. 3, No. 4A (2013), pp. 41-54. PMID: 25540717

86. Worcester EM, Bergsland KJ, **Gillen DL**, Coe FL. "Evidence for increased renal tubule and parathyroid gland sensitivity to serum calcium in human idiopathic hypercalciuria", *Am J Physiol Renal Physiol*, 305 (6) (2013), pp. F853-60.

87. Brummel S.* and **Gillen D.** "Flexibly Monitoring Group Sequential Survival Trials Using Constrained Boundaries", *Sequential Analysis*, Vol. 33 (2014), pp. 39-59.

88. Delfino RJ, Wu J, Tjoa T, Gullesserian SK*, Nickerson B, and **Gillen D.**, "Asthma Morbidity and Ambient air Pollution: Effect Modification by Residential Traffic-related Air Pollution", *Epidemiology*, Vol. 25 No. 1 (2014), pp. 48-57. PMID: 24240657

89. Park J, Ahmadi SF, Streja E, Molnar MZ, Flegal KM, **Gillen D.**, Kovesdy CP, Kalantar-Zadeh K., "Obesity paradox in end-stage kidney disease patients", *Prog Cardiovasc Dis.* Vol. 56, No. 4 (2014), pp. 415-25. PMID: 24438733

90. Lertdumrongluk P, Streja E, Rhee CM, Park J, Arah OA, Brunelli SM, Nissenson AR, **Gillen D.**, Kalantar-Zadeh K., "Dose of Hemodialysis and Survival: A Marginal Structural Model Analysis", *Am J Nephrol.* Vol. 39, No. 5 (2014), pp. 383-391. PMID: 24776927

91. Ahmadi SF, Zahmatkesh G, Streja E, Molnar MZ, Rhee CM, Kovesdy CP, **Gillen DL**, Steiner S, Kalantar-Zadeh K. "Body mass index and mortality in kidney transplant recipients: a systematic review and meta-analysis", *Am J Nephrol.* Vol. 40, No. 4 (2014), pp. 315-24. PMID: 25341624

92. Nguyen VQ, **Gillen DL**, Dick MB. "Memory for unfamiliar faces differentiates mild cognitive impairment from normal aging", *J Clin Exp Neuropsychol.* Vol. 36, No. 6 (2014), pp. 607-20. PMID: 24848571

93. Kim SB*, Bartell SM, **Gillen DL.** Estimation of a Benchmark Dose in the Presence or Absence of Hormesis Using Posterior Averaging. *Risk Analysis* (2014) Nov 10. PMID: 25384940

94. Bochicchio GV, Gupta N, Porte RJ, Renkens KL, Pattyn P, Topal B, Troisi RI, Muir W, Chetter I, **Gillen DL**, Zuckerman LA, Frohna PA. "The FINISH-3 Trial: A Phase 3, International, Randomized, Single-Blind, Controlled Trial of Topical Fibrocaps in Intraoperative Surgical Hemostasis." *J Am Coll Surg.* Vol. 220, No. 1 (2014), pp. 70-81. PMID: 25458801

95. Brikun I, Nusskern D, **Gillen D**, Lynn A, Murtagh D, Feczko J, Nelson WG, Freije D. "A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients." *Biomark Res.* Vol. 2, No. 1 (2014), pp. 25. PMID: 25548652

96. Wittkopp S, Staimer N, Tjoa T, Stinchcombe T, Daher N, Schauer JJ, Shafer MM, Sioutas C, **Gillen DL**, Delfino RJ. "Nrf2-related gene expression and exposure to traffic-related air pollution in elderly subjects with cardiovascular disease: An exploratory panel study." *J Expo Sci Environ Epidemiol.* Vol. 26, No. 2 (2016) pp. 141-9. PMID: 25564368

97. **Gillen DL**, Meyskens FL, Morgan TR, Zell J, Carrol R, Benya R, Chen WP, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, Rodriguez LM, Szabo E, Rosenberg DW, Lipkin SM. "A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting Epidermal Growth Factor Receptor Signaling in Aberrant Crypt Foci of the Colorectum." *Cancer Prevention Research*. Vol. 8, No. 3 (2015) pp. 222-30. PMID: 25604134

98. Rhee CM, Kim S*, **Gillen DL**, Oztan T, Wang J, Mehrotra R, Kuttykrishnan S, Nguyen DV, Brunelli SM, Kovesdy CP, Brent GA, Kalantar-Zadeh K. "Association of Thyroid Functional Disease with Mortality in a National Cohort of Incident Hemodialysis Patients." *J Clinincal Endocrinology and Metabolism*. Vol. 100, No. 4 (2015) pp. 1386-95. PMID: 25632971

99. Bristow RE, Chang J, Ziogas A, **Gillen DL**, Bai L*, Vieira VM. "Spatial analysis of advanced-stage ovarian cancer mortality in California." *Am J Obstetrics and Gynecology*. Vol. 213, No. 1 (2015) pp. 43.e1-8. PMID: 25644440

100. Ko B, Bergsland KJ, **Gillen DL**, Evan AP, Clark DL, Baylock J, Coe FL, Worcester EM. "Sex Differences in Proximal and Distal Nephron Function Contribute to the Mechanism of Idiopathic Hypercalcuria in Calcium Stone Formers". *American Journal of Physiology. Regulatory, Integrative and Comparative Physiology*. Vol. 309, No. 1 (2015) R85-92. PMID: 25947170

101. Lertdumrongluk P, Streja E, Rhee CM, Sim JJ, **Gillen D**, Kovesdy CP, Kalantar-Zadeh K. "Changes in Pulse Pressure during Hemodialysis Treatment and Survival in Maintenance Dialysis Patients." *Clin J Am Soc Nephrol*. (2015) Jun 1 (Epub ahead of print). PMID: 26034226

102. Moradi H, Abhari P, Streja E, Kashyap ML, Shah G, **Gillen D**, Pahl MV, Vaziri ND, Kalantar-Zadeh K. "Association of Serum Lipids with Outcomes in Hispanic Hemodialysis Patients of the West versus East Coasts of the United States." *Am J Nephrol*. (2015) Jun 1 (Epub ahead of print). PMID: 26044456

103. Entringer S, Epel ES, Lin J, Blackburn EH, Buss C, Shahbaba B, **Gillen DL**, Venkataramanan R, Simhan HN, Wadhwa PD. "Maternal Folate Concentration in Early Pregnancy and Newborn Telomere Length." *Ann Nutr Metab*. Vol. 66, No. 4 (2015) pp. 202-8. PMID: 26067849

104. Delfino RJ, Staimer N, Tjoa T, **Gillen DL**. "Relations of exhaled nitric oxide and FEV1 to personal endotoxin exposure in schoolchildren with asthma." *Occup Environ Med*. Vol. 72, No. 12 (2015) pp. 830-6. PMID: 26081623

105. Ellenberg SS, Culbertson R, **Gillen DL**, Goodman S, Schrandt S, Zirkle M. "Data Monitoring Committees for Pragmatic Clinical Trials." *Clinical Trials* Vol. 12, No. 5 (2015) pp. 530-6. PMID: 26374679

106. Yu Z, Demetriou M, **Gillen DL**, "Genome-Wide Analysis of Gene-Gene and Gene-Environment Interactions Using Closed-Form Wald Tests." *Genetic Epidemiology* Vol. 39, No. 6 (2015) pp. 446-55. PMID: 26095143

107. Passos D, Kilday K, **Gillen DL**, Cribbs DH, Vasilevko V. "Experimental hypertension increases spontaneous intracerebral hemorrhages in a mouse model of cerebral amyloidosis." *Journal of Cerebral Blood Flow & Metabolism.* Vol. 36, No. 2 (2016) pp. 399-404.

108. Moog NK, Buss C, Entringer S, Shahbaba B, **Gillen DL**, Hobel CJ, Wadhwa PD. "Maternal Exposure to Childhood Trauma Is Associated During Pregnancy with Placental-Fetal Stress Physiology." *Biol Psychiatry* Vol. 79, No. 10 (2015) pp. 831-9. PMID: 26444076

109. Ahmadi SF, Zahmatkesh G, Streja E, Mehrotra R, Rhee CM, Kovesdy CP, Gillen DL, Ahmadi E, Fonarow GC, Kalantar-Zadeh K. "Association of Body Mass Index with Mortality in Peritoneal Dialysis Patients: A Systematic Review and Meta-Analysis." *Perit Dial Int.* Vol. 36, No. 3 (2015) pp. 315-25. PMID: 26475847

110. Ennis J, **Gillen D**, Rubenstein A, Worcester E, Brecher ME, Asplin J, Coe F. "Clinical decision support improves physician guideline adherence for laboratory monitoring of chronic kidney disease: a matched cohort study." *BMC Nephrology* Vol. 16, No. 1 (2015) p. 163. PMID: 26471846

111. Wang J, Streja E, Rhee CM, Soohoo M, Feng M, Brunelli SM, Kovesdy CP, **Gillen D**, Kalantar-Zadeh K, Chen JL. "Lean Body Mass and Survival in Hemodialysis Patients and the Roles of Race and Ethnicity." *J Ren Nutr.* Vol. 26, No. 1 (2016) pp. 26-37. PMID: 26482246

112. Lumley T and **Gillen DL**, "Characterising Transitive Two-Sample Tests." *Statistics and Probability Letters.* Vol. 109 (2016) pp. 118-123.

113. Paterson EK, Fielder TJ, MacGregor GR, Ito S, Wakamatsu K, **Gillen DL**, Eby V, Boissy RE, Ganesan AK. "Tyrosinase Depletion Prevents the Maturation of Melanosomes in the Mouse Hair Follicle." *PloS One* Vol. 10, No. 11 (2015) PMID: 26619124

114. Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, Bragg-Gresham J, Balkrishnan R, Chen JL, Cope E, Eggers PW, **Gillen D**, Gipson D, Hailpern SM, Hall YN, He K, Herman W, Heung M, Hirth RA, Hutton D, Jacobsen SJ, Kalantar-Zadeh K, Kovesdy CP, Lu Y, Molnar MZ, Morgenstern H, Nallamothu B, Nguyen DV, O'Hare AM, Plattner B, Pisoni R, Port FK, Rao P, Rhee CM, Sakhuja A, Schaubel DE, Selewski DT, Shahinian V, Sim JJ, Song P, Streja E, Kurella Tamura M, Tentori F, White S, Woodside K, and Hirth RA., "US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States". *American J. of Kidney Disease* Vol. 67, No. 3, Supp. 1 (2016) pp. A7-8. PMID: 26925525

115. Kim SB*, Bartell SM, and **Gillen DL**, " Inference for the Existence of Hormetic Dose Response Relationships in Toxicology Studies". *Biostatistics* Vol. 17, No. 3 (2016) pp. 523-36. PMID: 26873961

116. Ahmadi SF, Zahmatkesh G, Ahmadi E, Streja E, Rhee CM, **Gillen DL**, De Nicola L, Minutolo R, Ricardo AC, Kovesdy CP, Kalantar-Zadeh K. "Association of Body Mass Index with Clinical Outcomes in Non-Dialysis-Dependent Chronic Kidney Disease: A Systematic Review and Meta-Analysis". *Cardiorenal Medicine* Vol. 6, No. 1, (2015) pp. 37-49. PMID: 27194995

117. Zhang X, Staimer N, **Gillen DL**, Tjoa T, Schauer JJ, Shafer MM, Hasheminassab S, Pakbin P, Vaziri ND, Sioutas C, Delfino RJ. "Associations of oxidative stress and inflammatory biomarkers with chemically-characterized air pollutant exposures in an elderly cohort". *Environmental Research*. Vol. 150 (2016) pp. 306-19. PMID: 27336235

118. Kim SB*, Molnar MZ, Fonarow GC, Streja E, Wang J, **Gillen DL**, Mehrotra R, Brunelli SM, Kovesdy CP, Kalantar-Zadeh K, Rhee CM. "Mean platelet volume and mortality risk in a national incident hemodialysis cohort". *International J. of Cardiology* Vol. 220, pp. 862-870. PMID 27400185

119. Nguyen VQ* and **Gillen DL** "Censoring-robust estimation in observational survival studies: Assessing the relative effectiveness of vascular access type on patency among end-stage renal disease patients", *Statistics in Bioscience*, In Press.

120. Kim SB* and **Gillen DL**, "A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials", *Sequential Analysis*, In Press.

121. Zhang X, Staimer N, Tjoa T, **Gillen DL**, Schauer JJ, Shafer MM, Hasheminassab S, Pakbin P, Longhurst JC, Sioutas C, Delfino R. "Associations Between Microvascular Function and Short-Term Exposure to Traffic-Related Air Pollution and Particulate Matter Oxidative Potential." *Environmental Health*. Vol. 15, No. 1 (2016) pp. 81. PMID: 27460097.

122. McLaren CE, Chen WP, OSullivan TD, **Gillen DL**, Su MY, Chen JH, Tromberg BJ. "Sample size and power determination when limited preliminary information is available". *BMC Medical Research Methodology*. 2017 Apr 26;17(1):75.

123. Bai L, **Gillen D**. "Survival analysis via cox proportional hazards additive models". *World Scientific Encyclopedia with Semantic Computing and Robotic Intelligence*. 2017 Mar;1(01):1650003.

124. Grill JD, Holbrook A*, Pierce A, Hoang D, **Gillen DL**. "Attitudes toward Potential Participant Registries". *Journal of Alzheimer's Disease*. 2017 Jan 1;56(3):939-46.

125. Obi Y, Kalantar-Zadeh K, Streja E, Rhee CM, Reddy UG, Soohoo M, Wang Y, Ravel V, You AS, Jing J, Sim JJ, Nguyen DV, **Gillen DL**, Saran R, Robinson B, Kovesdy CP. "Seasonal variations in transition, mortality and kidney transplantation among patients with end-stage renal disease in the USA". *Nephrology Dialysis Transplantation*. 2017 Feb 11;32(suppl 2):ii99-105.

126. Ikenoue S, Waffarn F, Ohashi M, Sumiyoshi K, Ikenoue C, Buss C, **Gillen DL**, Simhan HN, Entringer S, Wadhwa PD. "Prospective association of fetal liver blood flow at 30 weeks gestation with newborn adiposity". *American Journal of Obstetrics and Gynecology*. Volume 217, Issue 2, pp. 204.e1 204.e8, 2017.

127. Kalantar-Zadeh K, Kovesdy CP, Streja E, Rhee CM, Soohoo M, Chen JL, Molnar MZ, Obi Y, **Gillen D**, Nguyen DV, Norris KC, Sim JJ, Jacobsen SS. "Transition of care from pre-dialysis prelude to renal replacement therapy: the blueprints of emerging research in advanced chronic kidney disease". *Nephrology Dialysis Transplantation*. 2017 Apr 1;32(suppl 2):ii91-8.

128. Borofsky MS, Elmansy HM, York NE, Dauw CA, Williams JC, Worcester EM, **Gillen DL**, Lingeman JE. "MP19-08 Validation Of A Renal Papillary Grading System For Patients With Nephrolithiasis". *The Journal of Urology*. 2017 Apr 1;197(4):e232.

129. Cohen AJ, Borofsky MS, Anderson BB, Dauw CA, **Gillen DL**, Gerber GS, Worcester EM, Coe FL, Lingeman JE. "Endoscopic Evidence That Randall's Plaque is Associated with Surface Erosion of the Renal Papilla". *Journal of Endourology*. 2017 Jan 1;31(1):85-90.

130. Johnson WO, Ward EB*, **Gillen DL**. "Chapter 15: Bayesian Methods in Public Health". *Handbook of Statistics* 2017 Jan 1 (Vol. 36, pp. 407-442). Elsevier.

131. Nuño MM*, **Gillen DL**. "Chapter 5: Alternative Sampling Designs for Time-to-Event Data With Applications to Biomarker Discovery in Alzheimer's Disease". *Handbook of Statistics* 2017 Jan 1 (Vol. 36, pp. 105-166). Elsevier.

132. Ruiz R, Jahid S, Harris M, Marzese DM, Espitia F, Vasudeva P, Chen CF, de Feraudy S, Wu J, **Gillen DL**, Krasieva TB, Tromberg BJ, Pavan WJ, Hoon DS, Ganesan AK. "The RhoJ-BAD signaling network: An Achilles heel for BRAF mutant melanomas". *PLoS Genetics*. 2017 Jul 28;13(7):e1006913.

133. Nuño MM*, **Gillen DL**, Dosanjh KK, Brook J, Elashoff D, Ringman JM, Grill JD. "Attitudes toward clinical trials across the Alzheimers disease spectrum". *Alzheimer's Research & Therapy*. 2017 Dec;9(1):81.

134. Spotnitz WD, Zielske D, Centis V, Hoffman R, **Gillen DL**, Wittmann C, Guyot V, Campos DM, Forest P, Pearson A, Mcafee PC. "The SPOT GRADE: A New Method for Reproducibly Quantifying Surgical Wound Bleeding". *Spine*. 2018 Jun 1;43(11):E664-71.

135. Obi Y, Streja E, Mehrotra R, Rivara MB, Rhee CM, Soohoo M, **Gillen DL**, Lau WL, Kovesdy CP, Kalantar-Zadeh K. "Impact of Obesity on Modality Longevity, Residual Kidney Function, Peritonitis, and Survival Among Incident Peritoneal Dialysis Patients". *American Journal of Kidney Diseases*. 2018 71(6):802-813 .

136. Worcester EM, Bergsland KJ, **Gillen DL**, Coe FL. "Mechanism for Higher Urine pH in Normal Women Compared to Men". *American Journal of Physiology-Renal Physiology*. 2018 314(4):F623-F629.

137. Pierce AL, Cox CG, Nguyen H, Hoang D, Witbracht M, **Gillen DL**, Grill JD. "Participant Satisfaction With Learning Alzheimer Disease Clinical Trial Results". *Alzheimer Disease & Associated Disorders*. 2018 32(4):366-368.

138. Grill JD, Hoang D, **Gillen DL**, Cox CG, Gombosev A, Klein K, OLeary S, Witbracht M, Pierce A. "Constructing a Local Potential Participant Registry to Improve Alzheimers Disease Clinical Research Recruitment". *Journal of Alzheimer's Disease*. 2018 63(3):1055-1063.

139. Gao X∗, **Gillen D**, Ombao H. Fisher information matrix of binary time series. METRON. 2018 Dec 1;76(3):287-304.

140. Soohoo, M, Streja, E, Obi, Y, Rhee, CM, **Gillen DL**, Sumida, K, Nguyen, DV, Kovesdy, CP, Kalantar-Zadeh, K (2018). Predialysis Kidney Function and Its Rate of Decline Predict Mortality and Hospitalizations After Starting Dialysis. *Mayo Clin. Proc.*, 93, 8:1074-1085.

141. Cox, CG, Ryan, MM∗, **Gillen DL**, Grill, JD (2019). A Preliminary Study of Clinical Trial Enrollment Decisions Among People With Mild Cognitive Impairment and Their Study Partners. Am J Geriatr Psychiatry, 27, 3:322-332.

142. Cruz, M∗, **Gillen DL**, Bender, M, Ombao, H (2019). Assessing health care interventions via an interrupted time series model: Study power and design considerations. Statistics in medicine. 2019 May 10;38(10):1734-52.

143. Ardehali, A, Spotnitz, WD, Hoffman, RW, Olson, SA, Bochicchio, GV, Hermann, MC, Lakshman, S, Dang, NC, Centis, V, **Gillen DL**, Schorn, IJ, Spotnitz, RH (2019). Evaluation of the safety and efficacy of a new hemostatic powder using a quantitative surface bleeding severity scale. J Card Surg, 34, 1:50-62.

144. Huang, SS, Singh, R, McKinnell, JA, Park, S, Gombosev, A, Eells, SJ, **Gillen DL**, Kim, D, Rashid, S, Macias-Gil, R, Bolaris, MA, Tjoa, T, Cao, C, Hong, SS, Lequieu, J, Cui, E, Chang, J, He, J, Evans, K, Peterson, E, Simpson, G, Robinson, P, Choi, C, Bailey, CC, Leo, JD, Amin, A, Goldmann, D, Jernigan, JA, Platt, R, Septimus, E, Weinstein, RA, Hayden, MK, Miller, LG (2019). Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers. N. Engl. J. Med., 380, 7:638-650.

145. Saran, R, Robinson, B, Abbott, KC, Agodoa, LYC, Bragg-Gresham, J, Balkrishnan, R, Bhave, N, Dietrich, X, Ding, Z, Eggers, PW, Gaipov, A, **Gillen DL**, Gipson, D, Gu, H, Guro, P, Haggerty, D, Han, Y, He, K, Herman, W, Heung, M, Hirth, RA, Hsiung, JT, Hutton, D, Inoue, A, Jacobsen, SJ, Jin, Y, Kalantar-Zadeh, K, Kapke, A, Kleine, CE, Kovesdy, CP, Krueter, W, Kurtz, V, Li, Y, Liu, S, Marroquin, MV, McCullough, K, Molnar, MZ, Modi, Z, Montez-Rath, M, Moradi, H, Morgenstern, H, Mukhopadhyay, P, Nallamothu, B, Nguyen, DV, Norris, KC, O'Hare, AM, Obi, Y, Park, C, Pearson, J, Pisoni, R, Potukuchi, PK, Repeck, K, Rhee, CM, Schaubel, DE, Schrager, J, Selewski, DT, Shamraj, R, Shaw, SF, Shi, JM, Shieu, M, Sim, JJ, Soohoo, M, Steffick, D, Streja, E, Sumida, K, Kurella Tamura, M, Tilea, A, Turf, M, Wang, D, Weng, W, Woodside, KJ, Wyncott, A, Xiang, J, Xin, X, Yin, M, You, AS, Zhang, X, Zhou, H, Shahinian, V (2019). US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am. J. Kidney Dis., 73, 3S1:A7-A8.

146. Ko GJ, Obi Y, Chang TI, Soohoo M, Eriguchi R, Choi SJ, **Gillen DL**, Kovesdy CP, Streja E, Kalantar-Zadeh K, Rhee CM. Factors Associated With Withdrawal From Dialysis Therapy in Incident Hemodialysis Patients Aged 80 Years or Older. Journal of the American Medical Directors Association. 2019 Jun 1;20(6):743-50.

147. Berchtold NC, Prieto GA, Phelan M, **Gillen DL**, Baldi P, Bennett DA, Buchman AS, Cotman CW. Hippocampal gene expression patterns linked to late-life physical activity oppose age and AD-related transcriptional decline. Neurobiology of aging. 2019 Jun 1;78:142-54.

148. Grill JD, Nuño MM∗, **Gillen DL**. Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?. Alzheimer Disease & Associated Disorders. 2019 Apr 1;33(2):104-12.

149. Soohoo M, Moradi H, Obi Y, Rhee CM, Gosmanova EO, Molnar MZ, Kashyap ML, **Gillen DL**, Kovesdy CP, KalantarZadeh K, Streja E. Statin Therapy Before Transition to EndStage Renal Disease With Post-transition Outcomes. Journal of the American Heart Association. 2019 Mar 19;8(6):e011869.

150. Tustison NJ, Holbrook AJ∗, Avants BB, Roberts JM, Cook PA, Reagh ZM, Duda JT, Stone JR, **Gillen DL**, Yassa MA, Alzheimers Disease Neuroimaging Initiative. Longitudinal Mapping of Cortical Thickness Measurements: An Alzheimer's Disease Neuroimaging Initiative-Based Evaluation Study. J Alzheimers Dis. 2019;71(1):165-183.

151. Vegetabile BG, **Gillen DL**, Stern HS. Optimally balanced Gaussian process propensity scores for estimating treatment effects. Journal of the Royal Statistical Society: Series A (Statistics in Society). 2020 Jan;183(1):355-77.

152. Holbrook A*, Lumley T, **Gillen DL**. Estimating prediction error for complex samples. Canadian Journal of Statistics. Canadian Journal of Statistics. 2020 Jun;48(2):204-21.

153. Bai L*, **Gillen DL**, Bartell SM, Vieira VM. Mapping Smoothed Spatial Effect Estimates from Individual-Level Data: MapGAM. The R Journal (2020) 12:1, pages 32-48.

154. Ryan MM*, Grill JD, **Gillen DL**, Alzheimers Disease Neuroimaging Initiative. Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimers disease: study partner vs. participant accuracy. Alzheimer's research & therapy. 2019 Dec 1;11(1):85.

155. Grill JD, Kwon J*, Teylan MA, Pierce A, Vidoni ED, Burns JM, Lindauer A, Quinn J, Kaye J, **Gillen DL**, Nan B. Retention of Alzheimer Disease Research Participants. Alzheimer Disease & Associated Disorders. 2019 Oct 22.

156. Worcester EM, Bergsland KJ, **Gillen DL**, Coe FL. Evidence for disordered acid-base handling in calcium stone-forming patients. American Journal of Physiology-Renal Physiology. 2020 Feb 1;318(2):F363-74.

157. Ryan MM, Spotnitz WD, **Gillen DL**. Variance estimation for the Kappa statistic in the presence of clustered data and heterogeneous observations. Statistics in Medicine. 2020 Jun 30;39(14):1941-51.

158. Dang NC, Ardehali A, Bruckner BA, Parrino PE, **Gillen DL**, Hoffman RW, Spotnitz R, Cavoores S, Shorn IJ, Manson RJ, Spotnitz WD. Prospective, multicenter, randomized, controlled trial evaluating the performance of a novel combination powder vs hemostatic matrix in cardiothoracic operations. J Card Surg. 2020 Feb;35(2):313-319. doi: 10.1111/jocs.14376. Epub 2019 Nov 25. PMID: 31763732; PMCID: PMC7003826.

159. Nuño MM*, **Gillen DL**, Grill JD; Alzheimers Disease Cooperative Study. Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer's trials. Alzheimers Res Ther. 2019 Nov 27;11(1):92. doi: 10.1186/s13195-019-0544-6. PMID: 31775871; PMCID: PMC6881999.

160. Gombosev A, Salazar CR, Hoang D, Cox CG, **Gillen DL**, Grill JJ. Direct Mail Recruitment to a Potential Participant Registry. Alzheimer Dis Assoc Disord. 2019 Dec 9:10.1097/WAD.0000000000000368. doi: 10.1097/WAD.0000000000000368. Epub ahead of print. PMID: 31821186; PMCID: PMC7280074.

161. Gaizo DJD, Spotnitz WD, Hoffman RW, Hermann MC, Sher LS, Spotnitz RH, Genyk YS, Schorn IJ, **Gillen DL**, White BL, Miller BG, Manson RJ. SPOT GRADE II: Clinical Validation of a New Method for Reproducibly Quantifying Surgical Wound Bleeding: Prospective, Multicenter, Multispecialty, Single-Arm Study. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620936340. doi: 10.1177/1076029620936340. PMID: 32703005; PMCID: PMC7383655.

162. Salazar CR, Hoang D, **Gillen DL**, Grill JD. Racial and ethnic differences in older adults' willingness to be contacted about Alzheimer's disease research participation. Alzheimers Dement (N Y). 2020 May 8;6(1):e12023. doi: 10.1002/trc2.12023. PMID: 32399482; PMCID: PMC7207155.

163. Tang Y*, Vieira VM, Bartell SM, **Gillen DL**. A stratified generalized additive model and permutation test for temporal heterogeneity of smoothed bivariate spatial effects. Statistics in Medicine. 2020 Dec 10;39(28):4187-200.doi: 10.1002/sim.8718. PMID: 32794222.

164. Lazarides C, Ward EB*, Buss C, Chen WP, Voelkle MC, **Gillen DL**, Wadhwa PD, Entringer S. Psychological stress and cortisol during pregnancy: An ecological momentary assessment (EMA)-Based within- and between-person analysis. Psychoneuroendocrinology. 2020 Aug 24;121:104848. doi: 10.1016/j.psyneuen.2020.104848. Epub ahead of print. PMID: 32927180.

165. Holbrook AJ*, Tustison NJ, Marquez F, Roberts J, Yassa MA, **Gillen DL**; Alzheimer's Disease Neuroimaging Initiative. Anterolateral entorhinal cortex thickness as a new biomarker for early detection of Alzheimer's disease. Alzheimers Dement (Amst). 2020 Aug 25;12(1):e12068. doi: 10.1002/dad2.12068. PMID: 32875052; PMCID: PMC7447874.

166. Witbracht MG, Bernstein OM, Lin V, Salazar CR, Sajjadi SA, Hoang D, Cox CG, **Gillen DL**, Grill JD. Education and Message Framing Increase Willingness to Undergo Research Lumbar Puncture: A Randomized Controlled Trial. Front Med (Lausanne). 2020 Sep 18;7:493. doi: 10.3389/fmed.2020.00493. PMID: 33043024; PMCID: PMC7530193.

167. Ryan MM*, Cox CG, Witbracht M, Hoang D, **Gillen DL**, Grill JD. Using Direct-to-Consumer Genetic Testing Results to Accelerate Alzheimer Disease Clinical Trial Recruitment. Alzheimer Dis Assoc Disord. 2020 Oct 14. doi: 10.1097/WAD.0000000000000421. Epub ahead of print. PMID: 33060367.

168. Nuño MM*, **Gillen DL**. Robust estimation in the nested case-control design under a misspecified covariate functional form. Stat Med. 2021 Jan 30;40(2):299-311. doi: 10.1002/sim.8775. Epub 2020 Oct 26. PMID: 33105514.

169. Moog NK, Wadhwa PD, Entringer S, Heim CM, **Gillen DL**, Buss C. The challenge of ascertainment of exposure to childhood maltreatment: Issues and considerations. Psychoneuroendocrinology. 2020 Dec 7:105102. doi: 10.1016/j.psyneuen.2020.105102. Epub ahead of print. PMID: 33309437.

170. Ikenoue S, Waffarn F, Ohashi M, Tanaka M, **Gillen DL**, Buss C, Entringer S, Wadhwa PD. Placental corticotrophin releasing hormone is a modulator of fetal liver blood perfusion. J Clin Endocrinol Metab. 2020 Dec 12:dgaa908. doi: 10.1210/clinem/dgaa908. Epub ahead of print. PMID: 33313841.

171. Cox CG, Ryan MM*, **Gillen DL**, Grill JD. Is Reluctance to Share Alzheimer's Disease Biomarker Status with a Study Partner a Barrier to Preclinical Trial Recruitment? J Prev Alzheimers Dis. 2021;8(1):52-58. doi: 10.14283/jpad.2020.36. PMID: 33336225.

172. Bernstein OM*, Grill JD, **Gillen DL**. Recruitment and retention of participant and study partner dyads in two multinational Alzheimer's disease registration trials. Alzheimers Res Ther. 2021 Jan 8;13(1):16. doi: 10.1186/s13195-020-00762-8. PMID: 33419457; PMCID: PMC7791680.

173. Nuño, MM*, **Gillen DL**. On estimation in the nested casecontrol design under nonproportional hazards. Scandinavian Journal of Statistics. 2022 Mar;49(1):265-86.

174. Tustison NJ, Cook PA, Holbrook AJ, Johnson HJ, Muschelli J, Devenyi GA, Duda JT, Das SR, Cullen NC, **Gillen DL**, Yassa MA. The ANTsX ecosystem for quantitative biological and medical imaging. Scientific Reports. 2021 Apr 27;11(1):1-3.

175. Bruckner BA, Spotnitz WD, Suarez E, Loebe M, Ngo U, **Gillen DL**, Manson RJ. Evaluation of the Safety and Efficacy of a Novel Thrombin Containing Combination Hemostatic Powder Using a Historical Control. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211017238. doi: 10.1177/10760296211017238. PMID: 34024165; PMCID: PMC8150456.

176. Ryan MM*, **Gillen DL**, Grill JD. Reasons for undergoing amyloid imaging among cognitively unimpaired older adults. Ann Clin Transl Neurol. 2021 Aug;8(8):1646-1655. doi: 10.1002/acn3.51414. Epub 2021 Jul 6. PMID: 34227249; PMCID: PMC8351390.

177. Cruz M*, Pinto-Orellana MA, **Gillen DL**, Ombao HC. RITS: a toolbox for assessing complex interventions via interrupted time series models. BMC Med Res Methodol. 2021 Jul 8;21(1):143. doi: 10.1186/s12874-021-01322-w. PMID: 34238221; PMCID: PMC8265076.

178. Nuño, MM*, Grill JD, **Gillen DL**; Alzheimers Disease Neuroimaging Initiative. On the design of early-phase Alzheimer's disease clinical trials with cerebrospinal fluid tau outcomes. Clin Trials. 2021 Dec;18(6):714-723. doi: 10.1177/17407745211034497. Epub 2021 Jul 29. PMID: 34325548; PMCID: PMC8595611.

179. Nuño, MM*, **Gillen DL**. Censoring-robust time-dependent receiver operating characteristic curve estimators. Stat Med. 2021 Dec 30;40(30):6885-6899. doi: 10.1002/sim.9216. Epub 2021 Oct 17. PMID: 34658036; PMCID: PMC8671363.

180. Masouleh SA*, Holsclaw T, Shahbaba B, **Gillen DL**. A Flexible Joint Longitudinal-Survival Model for Analyzing Longitudinally Sampled Biomarkers. Open Journal of Statistics. 2021 Sep 27;11(5):778-805.

181. Gussin GM, Heim L, Tjoa T, McKinnell JA, Miller LG, **Gillen DL**, Sater MRA, Grad YH, Singh RD, Huang SS. Post-discharge decolonization of patients harboring methicillin-resistant Staphylococcus aureus (MRSA) USA300 strains: secondary analysis of the CLEAR Trial. Infection Control Hospital Epidemiology. 2021 Dec 16:1-4. doi: 10.1017/ice.2021.482. PMID: 34913422.

182. Hertel L*, Baldi P, **Gillen DL**. Reproducible Hyperparameter Optimization. Journal of Computational and Graphical Statistics. 2022 Jan 2;31(1):84-99.

183. Grill JD, Kind A, Hoang D, **Gillen DL**. Diversifying Recruitment Registries: Considering Neighborhood Health Metrics. J Prev Alzheimers Dis. 2022;9(1):119-125. doi: 10.14283/jpad.2021.50. PMID: 35098982.

184. Hakhu NR*, **Gillen DL**, Grill JD; Alzheimers Disease Cooperative Study. Dyadic Enrollment in a Phase 3 Mild Cognitive Impairment Clinical Trial. Alzheimer Dis Assoc Disord. 2022 Apr 29. doi: 10.1097/WAD.0000000000000506. Epub ahead of print. PMID: 35482891.

185. Salazar CR, Ritchie M, **Gillen DL**, Grill JD. Strategies Associated with Retaining Participants in the Longitudinal National Alzheimer's Coordinating Center Uniform Data Set Study. J Alzheimers Dis. 2022 Apr 25. doi: 10.3233/JAD-215537. Epub ahead of print. PMID: 35491778.

186. Lewis CK, Bernstein OM*, Grill JD, **Gillen DL**, Sultzer DL. Anxiety and Depressive Symptoms and Cortical Amyloid-Burden in Cognitively Unimpaired Older Adults. J Prev Alzheimers Dis. 2022;9(2):286-296. doi: 10.14283/jpad.2022.13. PMID: 35543002.

187. Miller LG, Singh R, Eells SJ, **Gillen DL**, McKinnell JA, Park S, Tjoa T, Chang J, Rashid S, Macias-Gil R, Heim L, Gombosev A, Kim D, Cui E, Lequieu J, Cao MC, Hong SS, Peterson EM, Evans KD, Launer B, Tam S, Bolaris M, Huang SS. Chlorhexidine and Mupirocin for Clearance of Methicillin Resistant Staphylococcus aureus Colonization After Hospital Discharge: A Secondary Analysis of the CLEAR Trial. Clin Infect Dis. 2022 May 31:ciac402. doi: 10.1093/cid/ciac402. Epub ahead of print. PMID: 35640877.

188. Cruz M*, Ombao HC, **Gillen DL**. A generalized interrupted time series model for assessing complex health care interventions. Statistics in Biosciences. 2022 May 25:1-29..

189. Bernstein O*, Vegetabile B, Grille JD, Slazar C, **Gillen DL**. Adjustment for biased sampling using NHANES derived propensity weights. Health Services and Outcomes Research Methodology. 2022 Jul 8:1-24.

190. Ritchie M*, **Gillen DL**, Grill JD. Recruitment across two decades of NIH-funded Alzheimer's disease clinical trials. Alzheimers Res Ther. 2023 Feb 2;15(1):28. doi: 10.1186/s13195-023-01177-x. PMID: 36732846; PMCID: PMC9893207.

191. Ikenoue S, Waffarn F, Sumiyoshi K, Ohashi M, Ikenoue C, Tanaka M, **Gillen DL**, Buss C, Entringer S, Wadhwa PD. Maternal insulin resistance in pregnancy is associated with fetal fat deposition: findings from a longitudinal study. Am J Obstet Gynecol. 2023 Apr;228(4):455.e1-455.e8. doi: 10.1016/j.ajog.2022.10.015. Epub 2022 Oct 23. PMID: 36283481.

192. Ritchie M*, Witbracht M, Nuo MM, Hoang D, **Gillen DL**, Grill JD. Effect of Aducanumab Approval on Willingness to Participate in Preclinical Alzheimer's Disease Trials. J Alzheimers Dis. 2022;90(3):1291-1300. doi: 10.3233/JAD-220801. PMID: 36245381.

193. Ryan MM* and **Gillen DL**. Sequential sampling in prospective observational studies. The Annals of Applied Statistics. 2023 Mar;17(1):153-77.

194. Zawadzki* RS, Grill JD, **Gillen DL**; Alzheimers Disease Neuroimaging Initiative. Frameworks for estimating causal effects in observational settings: comparing confounder adjustment and instrumental variables. BMC Med Res Methodol. 2023 May 22;23(1):122. doi: 10.1186/s12874-023-01936-2. PMID: 37217854; PMCID: PMC10201752.

195. Birnbaum AI*, Grill JD, **Gillen DL**. Cohort Effects in Alzheimer's Disease Trials: An Empirical Assessment Utilizing Data from the Alzheimer's Disease Cooperative Study. J Prev Alzheimers Dis. 2023;10(3):471-477. doi: 10.14283/jpad.2023.45. PMID: 37357287.

196. Ritchie M, **Gillen DL**, Grill JD. Estimating attrition in mild-to-moderate Alzheimer's disease and mild cognitive impairment clinical trials. Alzheimers Res Ther. 2023 Nov 21;15(1):203. doi: 10.1186/s13195-023-01352-0. PMID: 37990339; PMCID: PMC10662394.

197. Conniff KR*, Grill JD, **Gillen DL**. Retention of American Indian and Alaska Native participants in the National Alzheimer's Coordinating Center Uniform Data Set. Alzheimers Dement. 2024 Mar;20(3):1601-1613. doi: 10.1002/alz.13573. Epub 2023 Dec 5. PMID: 38053483; PMCID: PMC10984415.

198. Nishida MK*, Nuo MM, Grill JD, **Gillen DL**. Effects of informant replacement in Alzheimer's disease clinical trials. Alzheimers Dement (N Y). 2023 Dec 12;9(4):e12439. doi: 10.1002/trc2.12439. PMID: 38093736; PMCID: PMC10716564.

199. Ritchie M, Salazar CR, **Gillen DL**, Grill JD. Post-disclosure distress among racial and ethnic groups in a preclinical AD trial. Alzheimers Dement. 2024 Feb 8. doi: 10.1002/alz.13726. Epub ahead of print. PMID: 38329007.

200. Cox CG, Salazar CR, Birnbaum AI*, Witbracht M, Tam SP, Thai GT, Sajjadi SA, **Gillen DL**, Grill JD. Alzheimer's Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners. J Prev Alzheimers Dis. 2024;11(2):285-293. doi: 10.14283/jpad.2024.10. PMID: 38374734.

201. Lu TV*, Grill JD, **Gillen DL**; Alzheimers Disease Cooperative Study. Study Partner Type and Adverse Event Reporting in Mild-to-Moderate Alzheimer's Disease Clinical Trials. J Alzheimers Dis. 2024;98(2):729-738. doi: 10.3233/JAD-231283. PMID: 38427487; PMCID: PMC10977362.

202. Magana-Ramirez CM*, Irizarry-Martinez G, **Gillen DL**, Grill JD. Reasons for undergoing amyloid imaging among diverse enrollees in the A4 study. Alzheimers Dement. 2024 Sep;20(9):6060-6069. doi: 10.1002/alz.14077. Epub 2024 Jul 23. PMID: 39041310; PMCID: PMC11497770.

203. Ritchie M, Witbracht M, Russ E, Sajjadi SA, Thai GT, Tam S, **Gillen DL**, Grill JD. The utility of recruitment incentives in early Alzheimer's disease trials. Alzheimers Dement. 2024 Sep;20(9):6654-6658. doi: 10.1002/alz.14143. Epub 2024 Jul 27. PMID: 39072914; PMCID: PMC11497734.

204. Grill JD, Tam S, Thai G, Vides B, Pierce AL, Green K, **Gillen DL**, Teng E, Kremen S, Beigi M, Rissman RA, Lger GC, Balasubramanian A, Revta C, Morrison R, Jennings R, Pa J, Zhang J, Jin S, Messer K, Feldman HH. Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease. Neurology. 2025 Jan 14;104(1):e210152. doi: 10.1212/WNL.0000000000210152. Epub 2024 Dec 13. PMID: 39671543; PMCID: PMC11655133.

205. Nishida MK*, Nuo MM, Grill JD, **Gillen DL**. Impacts of informant replacement in two industry-sponsored Alzheimer's disease clinical trials. Alzheimers Dement (N Y). 2024 Nov 30;10(4):e70009. doi: 10.1002/trc2.70009. PMID: 39748852; PMCID: PMC11694524.

206. Witbracht M, Xu Y*, Morgan OB, Salazar CR, Hoang D, Kind A, **Gillen DL** Grill JD. Research Attitudes Questionnaire scores and retention in a recruitment registry. J Alzheimers Dis. 2025 Jan;103(2):406-418. doi: 10.1177/13872877241302422. Epub 2025 Jan 15. PMID: 39814522.

207. Grill JD, **Gillen DL**. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: the need for rigor. Alzheimers Res Ther. 2025 Feb 1;17(1):32. doi: 10.1186/s13195-024-01621-6. PMID: 39893378; PMCID: PMC11786341.

208. Dolmadjian LA*, Baumann MR, Grill JD, **Gillen DL**. Impact of study partner replacement in a mild cognitive impairment clinical trial. Alzheimers Dement (N Y). 2025 Feb 27;11(1):e70063. doi: 10.1002/trc2.70063. PMID: 40017898; PMCID: PMC11865708.

209. Gyllenhammer LE, Rasmussen JM, Lindsay KL, Chen WP, **Gillen DL**, Boyle KE, Buss C, Entringer S, Wadhwa PD. Maternal allostatic load in pregnancy is prospectively associated with child adiposity and metabolic function across infancy and early childhood. Psychoneuroendocrinology. 2025 Mar 26;177:107450. doi: 10.1016/j.psyneuen.2025.107450. Epub ahead of print. PMID: 40184958.

210. Zhang, Z*, Morgan, OB*, **Gillen, DL**. and (2025), Reweighted penalized regression for convenience samples. Can J Statistics e70005. https://doi.org/10.1002/cjs.70005

211. Birnbaum AI*, Gombosev A, Grant-Freeman ZT, Hoang D, **Gillen, DL**, Grill JD. Effectiveness of a local recruitment registry in older adults in Southern California. BMC Med Res Methodol. 2025 Jul 31;25(1):181. doi: 10.1186/s12874-025-02640-z. PMID: 40745267; PMCID: PMC12315308.

212. Cox CG, Birnbaum AI*, Salazar CR, Witbracht M, Tam SP, Thai GT, Sajjadi SA, **Gillen, DL**, Grill JD. Alzheimer's Disease Clinical Trial Decision-Making Among Patients with Mild Cognitive Impairment and Their Study Partners. AJOB Empir Bioeth. 2025 Oct-Dec;16(4):277-285. doi: 10.1080/23294515.2025.2576830. Epub 2025 Oct 28. PMID: 41147833; PMCID: PMC12593232.

213. Magana-Ramirez CM*, **Gillen, DL**, Hom CL, Jaimes L Jr, Chilukuri SS, McMahon N, Lin C, Kuhlman R, Hu T, Head E, Lott IT, Sultzer DL. Neuropsychiatric symptoms and emerging dementia in people with Down syndrome and older adults. Alzheimers Dement. 2025 Nov;21(11):e70871. doi: 10.1002/alz.70871. PMID: 41207870; PMCID: PMC12597398.

214. Hakhu NR*, **Gillen, DL**. Censoring-robust estimation in fixed sample time-to-event clinical trials with adaptive randomization. Biometrics. 2025 Oct 8;81(4):ujaf161. doi: 10.1093/biomtc/ujaf161. PMID: 41416721; PMCID: PMC12715681.

215. Zhang Z*, **Gillen, DL**. A Covariance-Based Penalty Estimator for Model Assessment With Censored Data. Biom J. 2026 Feb;68(1):e70103. doi: 10.1002/bimj.70103. PMID: 41459770.

216. Vanderlip CR, **Gillen, DL**, Stark CEL, Grill JD; HABS-HD Study Team. Uniform Amyloid Thresholds Across Populations. JAMA Neurol. 2026 Jan 20:e255329. doi: 10.1001/jamaneurol.2025.5329. Epub ahead of print. PMID: 41557361; PMCID: PMC12820775.

Appointments, Advisory Boards and Review Committees

Government Regulatory Boards and Scientific Advisory Sections:

- Chair, Biostatistical Methods Research and Design (BMRD) study section, NIH : 2018-2019.
- Member, Biostatistical Methods Research and Design (BMRD) study section, NIH : 2011-2012 (Ad Hoc), 2013 - 2018 (Standing).
- Ad Hoc Member (voting), Drug Safety Advisory Committee, FDA (20102-Present)
- Ad Hoc Member (voting), Endocrinologic and Metabolic Drugs Advisory Committee, FDA (2012-Present)
- Ad Hoc Member (voting), Cardiovascular and Renal Drugs Advisory Committee, FDA (2012-Present)
- Ad Hoc Member (voting), Reproductive Health Drugs Advisory Committee, FDA (2011-Present)
- Member (voting), Advisory Committee for Reproductive Health Drugs, FDA (2005-2010)

Data Monitoring and Scientific Advisory Committees:

- Member, Data Safety Monitoring Committee, Phase III trial (Dermatology), Amgen (2021 - Present)
- Member, Data Safety Monitoring Committee, Phase III trial (Renal Disease), Amgen (2020 - Present)
- Member, Data Safety Monitoring Committee, Phase III trial (CV Disease), Novo Nordisk (2019 - 2024)
- Chair, Data Safety Monitoring Committee, Phase I-II trial (Pediatric Cancer), Genentech Corporation (2019 - Present)
- Member, Data Safety Monitoring Committee, Phase III trial (CV Disease), Novo Nordisk (2019 - 2024)
- Member, Data Safety Monitoring Committee, Phase I trial (Cancer), CRISPR (2019 - Present)
- Member, Data Safety Monitoring Committee, Phase III trial (Cancer), Pfizer (2018 - 2023)
- Member, Data Safety Monitoring Committee, Phase III trial (COVID), AstraZeneca (2020 - 2022)
- Member, Data Safety Monitoring Committee, Phase III trial (Cancer), Novartis (2019 - Present)
- Member, Data Safety Monitoring Committee, Phase III trial (Cancer), Genentech/Roche (2019 - Present)
- Member, Data Safety Monitoring Committee, Phase II-III trial (Hemophelia), Biomarin (2019 - Present)
- Member, Data Safety Monitoring Committee, Phase III trial (Cancer), Seattle Genetics (2018 - Present)
- Member, Data Safety Monitoring Committee, Javelin Gastric 100, 300 Trials, Serano EMD (2016 - 2019)
- Member, Data Safety Monitoring Committee, Phase I-II CAR/TCR Trials in ALL, AML, CML, NSCLC, and Mesothelioma, Juno/Celgene (2016 - Present)
- Chair, Data Safety Monitoring Committee, iMatrix Atezo Trial, Genentech Corporation (2015 - 2020)
- Member, Data Safety Monitoring Committee, Prolia 20130173 Trial, Amgen (2015 - Present)
- Member, Data Safety Monitoring Committee, SANDPIPER Trial, Genentech Corporation (2014 - 2020)
- Member, Data Safety Monitoring Committee, Pompe 701 Trial, Biomarin (2014 - 2016)
- Member, Data Safety Monitoring Committee, PegPal 301, 302 Trials, Biomarin (2013 - Present)
- Member, Data Safety Monitoring Committee, KAITLIN Trial, Genentech Corporation (2014 - 2019)
- Member, Data Safety Monitoring Committee, Phase III GIOP Clinical Trial, Amgen (2013 - 2018)
- Member, Data Safety Monitoring Committee, Phase III Clinical Trial of Liraglutide for Diabetes Control in Children, Novo Nordisk (2012 - 2018)
- Member, Data Safety Monitoring Committee, Phase III Clinical Trial of MetMab, Genentech Corporation (2012 - 2014)
- Member, Data Safety Monitoring Committee, Phase III Clinical Trial of SGN-35, Seattle Genetics (2012 - 2016)
- Member, Data Safety Monitoring Committee, PDX-017 Phase III Clinical Trial, Allos Therapeutics, Inc. (2012 - 2014)
- Chair, Data Safety Monitoring Committee, Phase III Clinical Trial of T-DM1, Genentech Corporation (2011 - 2013)
- Member, Data Review Team, Phase II Clinical Trial AMG-785, Amgen (2011 - 2013)
- Member, Data Safety Monitoring Committee, Phase III Clinical Trial of GA101, Genentech Corporation (2010 - 2015)
- Member, Scientific Advisory Board, Litholink Corporation (2007 - Present)
- Chair, Data Safety Monitoring Committee, Phase III Trial of Galiximab in Combination with Rituximab, Biogen Idec (2006-2009)
- Member, Data Safety Monitoring Committee, Phase II/III Clinical Trial of Efalizumab, Genentech Corporation (2007-2008)
- Member, Data Safety Monitoring Committee, START Phase III Multicenter Trial: , Merck KGaA (2004 - 2013)
- Chair, Data Safety Monitoring Committee, Phase II/III Clinical Trial of Lumiliximab, Biogen Idec (2007-2010)
- Member, Data Safety Monitoring Committee, Phase IIB Clinical Trial of SGN-40, Seattle Genetics (2007-2009)
- Member, Data Safety Monitoring Committee, Phase II Clinical Trial of SGN-33, Seattle Genetics (2007-2009)
- Member, Data Safety Monitoring Committee, Multicenter Clinical Trial of rhThrombin, Zymogenetics
- Member, Data Safety Monitoring Committee, Chao Comprehensive Cancer Center, UC, Irvine (2004 - Present)
- Member, Scientific Advisory Panel: Translational Research for the Prevention and Control of Diabetes, UC Denver

Professional Service

Positions in Professional Organizations

Program Chair (Statistics in Epidemiology), Joint Meetings of the American Statistical Association; Chicago, IL (2016)

President, Western North American Region (WNAR) of the International Biometric Society (2011)

Chair, WNAR Regional Advisory Board (2006-2010)

Program Chair (WNAR), Joint Meetings of the American Statistical Association; Arlington, VA (2009)

Local Organizer, WNAR 2007 Annual Meeting; UC Irvine, Irvine, CA (2008)

Organizer and chair of invited paper session: "Statistical Issues in the Design, Evaluation, and Monitoring of Clinical Trials with Longitudinal and Survival Endpoints", ENAR; Tampa, FL (2006)

Associate Editor

Journal of the American Statistical Association - Case Studies and Applications (2009-2017)

Journal of Statistical Software (2012-2015)

Study Sections for Funding Agencies

Chair, Biostatistical Methods Research and Design (BMRD) study section, NIH : 2018-19.

Biostatistical Methods Research and Design (BMRD) study section, NIH : 2011-2012 (Ad Hoc), 2013 - 2019 (Standing).

National Heart, Lung and Blood Institute (NHLBI) study section, NIH : 2011.

National Cancer Institute (NCI) SPORE study section, NIH : 2011.

Southwest Oncology Group Data Repository study section, SWOG : 2011.

National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) study section, NIH : 2005.

Statistics Journal Reviewer

Biometrical Journal (2x)

BMC Medical Research Methods (2x)

Biometrics (3x)

Biostatsitics (1x)

Chance (1x)

Journal of the American Statistical Association (4x)

Journal of Biopharmaceutical Statistics (1x)

Journal of the Royal Statistical Society (2x)

Lifetime Data Analysis (1x)

Sequential Analysis (2x)

Statistics in Medicine (1x)

Clinical Journal Reviewer

Alzheimers and Dementia (2x)

Biology Letters (1x)

Environmental Health Perspectives (2x)

Journal of the American Medical Association (1x)

Journal of the American Society of Nephrology (1x)

Kidney International (2x)

Academic Service

Department Service

Department Chair, Statistics. (July 2016 - present)

Chair, Tenure Committee for Babak Shahbaba. (August 2013 - December 2013)

Chair, Tenure Committee for Zhaoxia Yu. (August 2012 - December 2012)

Member, Methods Qualifying Exam Committee, Dept of Statistics. (June 2007 - August 2013)

Member, Theory Qualifying Exam Committee, Dept of Statistics. (May 2009 - July 2013)

Chair, Mid-Career Committee for Babak Shahbaba. (August 2011 - October 2011)

Chair, Search Committee - Asst. Prof. in Residence. (January 2011 - September 2011)

Chair, Tenure Committee for Yaming Yu. (August 2010 - December 2010)

Chair, Mid-Career Committee for Zhaoxia Yu. (August 2010 - December 2010)

Member, Mid-Career Committee for Yaming Yu. (August 2008 - October 2008)

Member, Promotion Committee for Zhaoxia Yu. (August 2008 - October 2008)

Guest Lecturer, Dept of Epidemiology. (2007 - 2009)

School Service

Faculty Chair, Donald Bren School of Information and Computer Sciences, UCI. (2012-2013)

Annual Lecturer, Office of Clinical Research and Trials. (October 2007 - Present)

Annual Lecturer, Hematology/Oncology Fellows Research Series, UCI. (2005 - Present)

Member, Executive Committee, Donald Bren School of Information and Computer Sciences, UCI. (2011 - 2012)

Member, Executive Committee, Donald Bren School of Information and Computer Sciences, UCI. (2009 - 2010)

Member, External Relations Committee, Donald Bren School of Information and Computer Sciences, UCI. (2008 - 2009)

Member, FTE Committee, Program in Public Health, UCI. (2007 - 2008)

Member, Graduate Policy Committee, Donald Bren School of Information and Computer Sciences, UCI. (2004 - 2008)

Member, Educational Policy Committee, Donald Bren School of Information and Computer Sciences, UCI. (2005 - 2006)

University Service

Member, Assessment Committee, University of California, Irvine. (2011 - 2012)

Member, Council on Faculty Welfare, University of California, Irvine. (2006 - 2009)

Invited Talks and Seminars

Academic Departments, Centers and Government Institutions

1. Memory Impairments and Neurological Disease (MIND) Center, "FDAs Accelerated Approval Program and the Critical Role of Advisory Committees in the Regulatory Process" (Irvine, CA; October 2025)

2. San Diego State University, Department of Biostatistics, "Survival Methods for Scientific Replicability" (San Diego, CA; November 2024)

3. Vanderbilt University, Department of Biostatistics, "On Censoring-Robust Estimation Under the Nested Case-Control Design" (Nashville, TN; November 2021)

4. University of California, Santa Barbara, Department of Statistics, "Bayesian estimation of case-crossover designs with repeated events" (Santa Barbara, CA; Nov 2019)

5. University of California, Riverside, Department of Statistics, "Notes on the Case-Crossover Design for Air Pollution Studies" (Riverside, CA; Oct 2019)

6. Vanderbilt University, Department of Biostatistics, "Bayesian estimation of case-crossover designs with repeated events" (Nashville, TN; April 2017)

7. San Diego State University, Department of Mathematics and Statistics, "Bayesian estimation of case-crossover designs with repeated events" (San Diego, CA; March 2017)

8. University of California, San Francisco, Department of Epidemiology and Biostatistics, "A class of flexible joint longitudinal-survival models for quantifying the association between serum biomarkers and mortality" (San Francisco, CA; May 2016)

9. University of Washington, Department of Biostatistics, "Characterising transitive two-sample tests" (Seattle, WA; Apr 2016)

10. University of Otago, Department of Mathematics and Statistics, "Flexibly modeling the time-varying effect of renal transplantation on the risk of lymphoma using random split-times" (Dunedin, NZ; Mar 2015)

11. California State University, Fullerton, Department of Mathematics, "Flexibly modeling the time-varying effect of renal transplantation on the risk of lymphoma using random split-times" (Fullerton, CA; Nov 2014)

12. Harvard University, Department of Biostatistics, "Balancing Individual- and Population-Level Ethics in Phase I Clinical Trials" (Boston, MA; Sept 2014)

13. Harvard University, Department of Biostatistics, "A Gaussian Process Model for Estimating Within-Subject Volatility in Indices of Protein-Energy Malnutrition Among End-Stage Renal Disease Patients" (Boston, MA; Sept 2014)

14. RAND Corp., "A Gaussian Process Model for Estimating Within-Subject Volatility in Indices of Protein-Energy Malnutrition Among End-Stage Renal Disease Patients" (Santa Monica, CA; Sept 2014)

15. University of California, Irvine, Department of Statistics, "A Gaussian Process Model for Estimating Within-Subject Volatility in Indices of Protein-Energy Malnutrition Among End-Stage Renal Disease Patients" (Irvine, CA; Sept 2014)

16. University of Colorado, Denver, Department of Biostatistics and Informatics, "Balancing Individual- and Population-Level Ethics in Phase I Clinical Trials" (Denver, CO; Dec 2013)

17. University of California, San Diego, Division of Biostatistics, "Flexibly Monitoring Sequential Clinical Trials with Weighted Survival Statistics" (San Diego, CA; Feb 2013)

18. University of California, Riverside, Department of Statistics, "Random Split-Times for Flexibly Modeling Non-Proportional Hazards Covariate Effects" (Riverside, CA; Nov 2011)

19. University of California, Los Angeles, Department of Biostatistics, "Random Split-Times for Flexibly Modeling Non-Proportional Hazards Covariate Effects" (Los Angeles, CA; Nov 2011)

20. University of California, Irvine, Department of Statistics, "Designing and Monitoring Clinical Trials with Survival Endpoints: Statistical Issues, Proposals, and Opportunities" (Irvine, CA; Oct 2011)

21. San Diego State University, Department of Mathematics and Statistics, "Random Split-Times for Flexibly Modeling Non-Proportional Hazards Covariate Effects" (San Diego, CA; Mar 2011)

22. University of Washington, Department of Biostatistics, "A Random Walk Approach to the Design and Monitoring of Group Sequential Trials" (Seattle, WA; Feb 2007)

23. FDA, "Statistical Issues in the Analysis of Oral Contraceptive Trials" (Washington, DC; Jan 2007)

24. Cal Poly State University, San Luis Obispo, Department of Statistics, "On the Analysis of Survival Data - Limitations of Commonly Used Methodology" (San Luis Obispo, CA; Dec 2006)

25. University of California, Riverside, Department of Statistics, "A Random Walk Approach to the Design and Monitoring of Group Sequential Trials" (Riverside, CA; Oct 2006)

26. University of California, Irvine, Department of Medicine Grand Rounds, "Design and Analysis of Clinical Studies with Time-Varying Effects: Case Studies and Examples" (Orange, CA; May 2006)

27. Vanderbilt University, Department of Biostatistics, "A Random Walk Approach to the Design and Monitoring of Group Sequential Trials" (Nashville, TN; Oct 2005)

28. NIH, NIAID, "Evaluation and Monitoring of Group Sequential trials Under Non-Proportional Hazards" (Washington, DC; July 2005).

29. University of California, Los Angeles, Department of Biostatistics, "A Random Walk Approach to the Design and Monitoring of Group Sequential Trials" (Los Angeles, CA; Feb 2005)

30. Brown University, Center for Statistical Sciences, "Issues in the Design and Analysis of Group Sequential Survival Trials" (Providence, RI; Nov 2004)

31. University of California, Irvine, Division of Epidemiology, "A Joint Longitudinal and Survival Model for Flexibly Incorporating Non-Proportional Hazards" (Irvine, CA; Nov 2004)

32. Claremont McKenna College, Department of Mathematics, "When is Enough, Enough? The Use of Group Sequential Methods in Clinical Trials" (Claremont, CA; Oct 2004)

33. University of Wisconsin, Madison, Department of Biostatistics and Medical Informatics, "The Use of Weighted Logrank Statistics in Group Sequential Trials" (Madison, WI; Apr 2004)

International Meetings

1. Biostatistics Symposium of Southern California (BSSC), (Keynote) "Are Futility Bounds Futile?" (Newport Beach, CA; January 2026)

2. The Science of Reproducibility in Health Real World Data Symposium, "Recognizing and Overcoming Problems with Real World Data" (Irvine, CA; January 2026)

3. American Association for the Advancement of Sciences (AAAS) 2025 Seminar Series, "FDAs Accelerated Approval Program and the Critical Role of Advisory Committees in the Regulatory Process" (Virtual; November 2025)

4. Bay Area Biotech-Pharma Statistics Workshop (BBSW), "Are Futility Bounds Futile?" (San Francisco, CA; November 2025)

5. Lifetime Data Science Conference, "Modified Nested Case-Control Designs for Maximizing Precision to Assess Effect Modification" (New Jersey; June 2025)

6. JSM, "Censoring Robust Estimation in Joint Longitudinal-Survival Models with Time-Varying Effects" (Toronto, CA; August 2023)

7. Lifetime Data Science Conference, "Censoring Robust Time-Dependent ROC Estimation" (Raleigh, NC; June 2023)

8. JSM, "Design and Evaluation of Adaptive Design Clinical Trials: Software Demonstration" (Virtual; August 2020)

9. International Chinese Statistical Association, "Lessons Learned from Adaptive RCT Designs" (Hangzhou, China; December 2019)

10. JSM, "The NIH Funding Mechanism" (Denver, CO; August 2019)

11. ENAR Junior Researchers Conference, "The NIH Funding Mechanism" (Philadelphia, PA; March 2019)

12. So Cal ASA Meeting, "Adaptive Designs in the Regulatory Setting" (Irvine, CA; May 2019)

13. CMS 2018, "A flexible joint longitudinal-survival modeling framework for incorporating multiple longitudinal biomarkers" (Pisa, Italy; December 2018)

14. The Sixth International Workshop in Sequential Methodologies, "Adaptive Designs Under Time-Varying Treatment Effects" (Paris, France; June 2017)

15. JSM, "A Flexible Joint Longitudinal-Survival Model for Quantifying the Association Between Serum Biomarkers and Mortality" (Chicago, IL; August 2016)

16. JSM, "A Modified Continual Reassessment Method for Balancing Individual- and Population-Ethics in Phase I Clinical Trials" (Seattle, WA; August 2015)

17. JSM, "A Gaussian Process Model for Estimating Within-Subject Variation in Indices of Protein-Energy Malnutrition Among ESRD Patients" (Montreal, Canada; August 2013)

18. WNAR, "On the Use of Prior Information for Flexibly Monitoring Group Sequential Survival Trials" (Davis, CA; June 2008)

19. ENAR, "A Constrained Boundaries Approach for Monitoring Time to Event Outcomes" (Washington, DC; March 2008)

20. ENAR, "A Random Walk Approach to the Design and Monitoring of Group Sequential Trials" (Tampa, FL; March 2006)

21. Joint Statistical Meetings, Session Chair - "Bayesian Hierarchical Modeling in Biostatistics" (Minneapolis, MN; Aug 2005)

22. WNAR, "The Design and Analysis of Group Sequential Survival Trials: A Random Walk Approach" (Fairbanks, AK; Jun 2005)

23. California Association of Regional Cancer Registries (CARCR) Research Symposium, "Methods for Modeling Time-Varying Covariate Effects in Cohort Studies" (Newport Beach, CA; February 2005)

24. American Society of Nephrology, Invited lecture, "Perils and Pitfalls in Estimating Renal Function" (San Diego, CA; Nov 2003)

25. WNAR, Panel discussion on *Effective Teaching Practices* (Los Angeles, CA; Jun 2002).

Contributed Presentations at National and International Meetings

1. Joint Statistical Meetings, "Bayesian estimation of case-crossover designs with repeated events" (Baltimore, MD; Aug 2017).

2. International Biometric Conference, "A Two-Step Estimator of Haplotype Relative Risks with Clustered Survival Data" (Florionopolis, Brazil; Dec 2010).

3. American Society of Nephrology, "The Survival Advantage of Pediatric Recipients of a First Kidney Transplant among Children Awaiting Kidney Transplantation", (poster) (San Diego, CA; Nov 2006)

4. American Society of Nephrology, "Increased Risk of Thrombosis among Patients with End-Stage Renal Disease", (poster) (San Diego, CA; Nov 2006)

5. American Society of Nephrology, "Decreased Renal Function Among Adults with a History of Nephrolithiasis: A Study of NHANES III", (poster) (St. Louis, MO; Nov 2004)

6. American Society of Nephrology, Neprholithiasis and Increased Blood Pressure Among Females with Increased BMI", (poster) (St. Louis, MO; Nov 2004)

7. Joint Statistical Meetings, "A Joint Longitudinal and Survival Model for Flexibly Incorporating Non-Proportional Hazards" (Toronto, CAN; Aug 2004).

8. International Biometric Conference, "Estimation of Fixed Time Survival via Random Walks" (Cairnes, AUS; Jul 2004).

9. Joint Statistical Meetings, "Evaluating a Clinical Trial in the Presence of Non-Proportional Hazards" (San Francisco, CA; Aug 2003).

10. WNAR, "Information Growth in a Family of Weighted Logrank Statistics Under Interim Analyses" (Golden, CO; Jun 2003).

11. WNAR, "Non-Transitivity in a Class of Weighted Logrank Statistics Under Non-Proportional Hazards" (Los Angeles, CA; Jun 2002).

Grant Funding

Oct 2022 - Sep 2028	National Science Foundation (S-STEM - 2221337) Title: Collaborative Research: Pacific Alliance for Low-Income Inclusion in Statistics & Data Science Role: Principle Investigator
Jul 2022 - Jun 2027	National Institutes of Health (NIA - R01AG075107) Title: Statistical Methods for Alzheimers Research Role: Principle Investigator (Multi-PI grant with B. Nan)
Jul 2022 - Jun 2027	National Institutes of Health (NIMH - R01HD107176) Title: Stress and Human Stem/Progenitor Cells: Biobehavioral Mechanisms Role: Co-Investigator with P. Wahdwa as PI)
Jun 2022 - Jun 2027	National Institutes of Health (NIMH - R01MD017387) Title: Biological Embedding of Social Disadvantage in Human Stem Cells: Implications for Health Disparities Role: Co-Investigator with P. Wahdwa as PI)
Apr 2022 - Mar 2027	National Institutes of Health (NIA - R01AG077628) Title: Recruiting and retaining participants from disadvantaged neighborhoods in registries Role: Principle Investigator (Multi-PI grant with J. Grill and A. Kind)
Apr 2022 - Mar 2027	National Institutes of Health (NIA - R25AI170491) Title: Irvine Summer Institute in Biostatistics and Data Science Role: Principle Investigator (Multi-PI grant with V. Minin, M. Dogucu, and B. Shahbaba)
Jan 2022 - Dec 2026	National Institutes of Health (NHLBI - R01HL153724) Title: The state of energy in the right ventricle of patients with pulmonary arterial hypertension Role: Co-Investigator with A. Kheradvar as PI
May 2020 - June 2025	National Institutes of Health (NIA - P50 AG16573) Title: Alzheimers Disease Research Center at the University of California, Irvine Role: Co-Investigator (Data and Statistics Core Director) with F. LaFerla as PI
May 2018 - Apr 2022	National Institutes of Health (NIA - R01AG059407) Title: Effects of Alzheimers disease clinical trial study partners Role: Principle Investigator (Multi-PI grant with J. Grill)
July 2017 - June 2022	National Institutes of Health (NIA - R01AG053555) Title: Neuroimaging biomarkers for cognitive decline in elderly with amyloid pathology Role: Principle Investigator (Multi-PI with M. Yassa)
July 2017 - June 2019	National Institutes of Health (NIA - R21AG056931) Title: The study partner requirement in preclinical Alzheimer's disease trials Role: Principle Investigator (Multi-PI with J. Grill)
April 2015 - March 2020	National Institutes of Health (NIA - P50 AG16573) Title: Alzheimers Disease Research Center at the University of California, Irvine Role: Co-Investigator (Data and Statistics Core Director) with F. LaFerla as PI
July 2016 - February 2021	National Institutes of Health (NIMD - 1R01 MD-010738) Title: Maternal Acculturation in Pregnancy and Infant Adiposity in Mexican-Americans Role: Co-Investigator with P. Wadhwa as PI
June 2015 - May 2020	National Institutes of Health (NIMH - 1R0I MH-105538) Title: Intergenerational Effects of Maternal Childhood Trauma on the Fetal Brain Role: Co-Investigator with P. Wadhwa as PI
January 2016 - December 2016	National Institutes of Health (NCI - P30 CA-62203) Title: University of California Irvine Cancer Center Support Grant Role: Co-Investigator (Director of Biostatistics Shared Resource) with R. Van Etten as PI

September 2016 - August 2018	National Institutes of Health (NIOD - 1UG3 OD-023349) Title: ECHO: Pre-and Postnatal Exposure Periods for Child Health: Common Risks and Shared Mechanisms Role: Co-Investigator with P. Wadhwa as PI
September 2016 - March 2017	National Institutes of Health (NIAG - 1R01 AG-050455) Title: Social Disadvantage and Fetal Programming of Newborn-Infant Telomere Biology Role: Co-Investigator with P. Wadhwa as PI
April 2014 - March 2015	National Institutes of Health (NIDDK - U01DK102163) Title: Transition to CKD Role: Co-Investigator with K. Kalantar-Zadeh as PI
December 2010 - November 2015	National Institutes of Health (NICHHD - RO1 MH-091351) Title: Fetal Programming of the Newborn and Infant Human Brain Role: Co-Investigator with C. Buss as PI
July 2010 - June 2015	National Institutes of Health (NICHHD - RO1 HD-065825) Title: Prenatal Stress Biology, Infant Body Composition and Obesity Risk Role: Co-Investigator with S. Etringer as PI
April 2010 - March 2015	National Institutes of Health (NIA - P50 AG16573) Title: Alzheimers Disease Research Center at the University of California, Irvine Role: Co-Investigator (Data and Statistics Core Director) with C. Cotman as PI
April 2013 - January 2015	National Institutes of Health (NICHD - 5R01HD065825-02) Title: Fetal Programming of Newborn and Infant Telomere Biology Role: Co-Investigator with C. Buss as PI
February 2010 - January 2015	National Institutes of Health (NIMH - RO1 HD-060628) Title: Ecological Momentary Assessment (EMA) of Biobehavioral Processes in Human Pregnancy Role: Co-Investigator with P. Wadhwa as PI
September 2010 - August 2014	National Institutes of Health (AHRQ - R01 HS-019388) Title: Project CLEAR Changing Lives by Eradicating Antibiotic Resistance Role: Co-Investigator with S. Huang as PI
September 2009 - August 2014	National Institutes of Health (NCHHD-R01 HD065160) Title: Predicting Cognitive Decline in Adults with Down Syndrome Role: Co-Investigator with I. Lott as PI
April 2012 - March 2014	National Institutes of Health (NCI - R03 CA159425) Title:Censoring Robust Estimation of Covariate Effects on Discrete Survival Endpoints Role: PI
August 2010 - January 2014	National Institutes of Health (NCI - P30 CA-62203) Title: University of California Irvine Cancer Center Support Grant Role: Co-Investigator (Director of Biostatistics Shared Resource) with F. Meyskens as PI
June 2010 - June 2012	State of California Air Resources Board (Contract No. 09-341) Title:Peripheral Blood Gene Expression in Subjects with Coronary Artery Disease and Exposure to Particulate Air Pollutant Components and Size Fractions Role: Co-Investigator with R. Delfino as PI
January 2011 - December 2011	National Institutes of Health (NIEHS - R21 ES019711) Title: Acute Asthma Outcomes, Endotoxin, and Oxidative Potential of Pollutant Particles Role: Co-Investigator with R. Delfino as PI
December 2009 - November 2011	BP Inc/South Coast Air Quality Management District (BPG-46329) Title: Risk of hospital encounters for asthma among children from exposure to traffic-related air pollutants near the home Role: Co-Investigator with R. Delfino as PI
June 2009 - May 2011	National Institutes of Health (NIEHS - R21 ES016420) Title:Air Pollution and Peripheral Blood Gene Expression in Subjects with CAD Role: Co-Investigator with R. Delfino as PI

April 2009 - March 2011	National Institutes of Health (NCI - R03 CA135691) Title: Evaluation of Methods for Estimating Haplotype Effects in Survival Studies Role: PI
June 2005 - May 2010	National Institutes of Health (NIDDK - PO1 DK56788) Title: Pathogensis of Nephrolithiasis Role: Co-Investigator with F. Coe as PI
March 2009 - March 2010	Eli Lilly (MA-00998-2009) Title: Heterogeneity in Treatment Response Role: Co-Investigator with S. Greenfield as PI
April 2005 - March 2010	National Institutes of Health (NIA - P50 AG16573) Title: Alzheimers Disease Research Center at the University of California, Irvine Role: Co-Investigator (Data and Statistics Core Director) with C. Cotman as PI
January 2008 - December 2008	UCI ICS Fund for Excellence in Collaborative Research Title: Multiple Outputation for Inference Regarding Haplotype Effects in Survival Studies Role: PI
September 2006 - August 2008	National Institutes of Health (NCI - CA123248) Title:Hypomorphic Mismatch Repair Gene Mutations And Single Molecule MSI Role: Co-PI with S. Lipkin and E. Chao
June 2005 - April 2007	National Institutes of Health (EHS - ES11615) Title:Pediatric Asthma, Particulate Air Pollution and NO_2 Role: Co-Investigator with R. Delfino as PI
September 2003 - August 2004	National Institutes of Health (NK30 HL04093) Title: Clinical Research Training Program Role: Co-Investigator with F. Coe as PI
May 2003 - December 2003	National Institutes of Health (NHLBI - RO1 HL69719) Title: Group Sequential Methods for Longitudinal Data Role: Research Assistant with S. Emerson as PI

Teaching

Course Development

University of California, Irvine

- *Introduction to Probability & Statistics III (STAT 120C):* The third quarter of a three quarter sequence in mathematical statistics for upper division undergraduate students. This course develops the theory behind ANOVA, linear regression, and categorical data methods. First offered Spring 2005.

- *Statistical Methods for Data Analysis II (STAT 111/202):* The second quarter of a three quarter sequence in regression methods for data analysis. This course focuses on the application of regression models for non-normal outcomes and is geared toward advanced undergraduates and graduate students outside the Department of Statistics. First offered Winter 2008.

- *Introduction to Probability and Statistical Theory II (STAT 200B):* The second quarter of a three quarter sequence in mathematical statistics. This course focuses on the theory of estimation and asymptotic distributional theory. First offered in Winter 2011.

- *Introduction to Probability and Statistical Theory III (STAT 200C):* The third quarter of a three quarter sequence in mathematical statistics. This course focuses on the theory of linear models and is geared toward graduate students in statistics. First offered with focus on theory of linear models in Spring 2009.

- *Statistical Methods II (STAT 211):* The second quarter of a three quarter sequence in the theory and application of statistical methods for graduate students in statistics. This course covers the theory and application of generalized linear models. First offered Winter 2005.

- *Modern Data Analysis Methods (STAT 235):* A one quarter course in the theory and application of modern statistical methods used in data analysis including resampling techniques, smoothing, cross-validation, and simulation as tool for evaluating these procedures. The course content is geared towards first year graduate students in statistics. First offered Fall 2007.

- *Biostatistics (STAT 250):* A one quarter course in the theory and application of statistical methods commonly used in public health research. The course content is geared towards first year graduate students in statistics. First offered Fall 2005.

- *Survival Analysis (STAT 255):* A one quarter course in the theory and application of statistical methods for analyzing censored and truncated data. The course content is geared towards first year graduate students in statistics. First offered Spring 2011.

- *Statistical Consulting (STAT 275):* A one quarter course in the practice of statistical consulting. The course content is geared towards second year and beyond graduate students in statistics. First offered Winter 2014.

Formal Teaching

University of California, Irvine

- Stat 120C – Introduction to Probability & Statistics III : Spring 2005, 2006, 2007, Department of Statistics, University of California, Irvine.

- Stat 200B – Intermediate Probability and Statistical Theory II : Winter 2011, 2012, 2020, 2025, Department of Statistics, University of California, Irvine.

- Stat 200BP – Intermediate Probability and Statistical Theory II : Winter 2024, Department of Statistics, University of California, Irvine.

- Stat 200C – Theory of Linear Models : Spring 2009, 2013, Department of Statistics, University of California, Irvine.

- Stat 111/202 Statistical Methods for Data Analysis II (Generalized Linear Models) : Winter 2008-2012, Department of Statistics, University of California, Irvine.

- Stat 210B – Categorical Data Analysis : Winter 2023 Department of Statistics, University of California, Irvine.

- Stat 211 – Statistical Methods II (Generalized Linear Models) : Winter 2005-10, 2014, 2016-18, 2022, 2024 Department of Statistics, University of California, Irvine.

- Stat 212 – Statistical Methods III (Analysis of Longitudinal Data) : Spring 2007, 2012, 2013, 2017-18, Department of Statistics, University of California, Irvine.

- Stat 235 – Modern Data Analysis Methods : Fall 2007, Department of Statistics, University of California, Irvine.

- Stat 250 – Biostatistics : Fall 2005, Spring 2009, Department of Statistics, University of California, Irvine.

- Stat 255 – Survival Analysis : Spring 2011, 2016, 2020, 2023 Department of Statistics, University of California, Irvine.

- Stat 275 – Statistical Consulting : Winter 2014, Department of Statistics, University of California, Irvine.

University of Chicago

- HSD 324 – Survival Analysis : Spring 2004, Departments of Health Studies and Statistics, University of Chicago.

- Clinical Research Training Program : Fall/Winter/Spring 2003-04, Departments of Health Studies and Statistics, University of Chicago.

California Polytechnic University, San Luis Obispo

- Math 116 – College Algebra : Winter/Spring 1998, Department of Mathematics, Cal Poly State University, San Luis Obispo.

- Math 100 – Beginning/Intermediate Algebra : Fall/Winter/Spring 1996 - 1998, Student Academic Services, Cal Poly State University, San Luis Obispo.

- Math 116 – College Algebra : Summer 1996-97, Summer Institute, Cal Poly State University, San Luis Obispo.

Shortcourses (* Indicates course was co-taught)

- IMPACT-AD, *Statistical Methods in Clinical Trials*; San Diego, CA; September, 2024.

- IMPACT-AD, *Statistical Methods in Clinical Trials*; San Diego, CA; September, 2023.

- IMPACT-AD, *Statistical Methods in Clinical Trials*; San Diego, CA; September, 2022.
- IMPACT-AD, *Statistical Methods in Clinical Trials*; Virtual; September, 2021.
- UCI Center for Statistical Consulting, *Adaptive and Sequential Clinical Trials Design*; Irvine, CA; November 2020.
- IMPACT-AD, *Statistical Methods in Clinical Trials*; Virtual; September, 2020.
- UCI Center for Statistical Consulting, *Introduction to Clinical Trials*; Irvine, CA; November 2019.
- Seattle Institute in Biostatistics, *Introduction to Clinical Trials - Days 1* * *and 2* *; Seattle, WA; July 2018.
- Seattle Institute in Biostatistics, *Group Sequential Methods for Clinical Trial Design and Monitoring* *; Seattle, WA; July 2018.
- Seattle Institute in Biostatistics, *Introduction to Clinical Trials - Days 1* * *and 2* *; Seattle, WA; July 2017.
- Seattle Institute in Biostatistics, *Group Sequential Methods for Clinical Trial Design and Monitoring* *; Seattle, WA; July 2017.
- Seattle Institute in Biostatistics, *Group Sequential and Adaptive Methods for Censored Survival Data* *; Seattle, WA; July 2016.
- Seattle Institute in Biostatistics, *Introduction to Clinical Trials - Days 1* * *and 2* *; Seattle, WA; July 2016.
- Seattle Institute in Biostatistics, *Group Sequential Methods for Clinical Trial Design and Monitoring* *; Seattle, WA; July 2016.
- Seattle Institute in Biostatistics, *Group Sequential and Adaptive Methods for Censored Survival Data* *; Seattle, WA; June 2015.
- Seattle Institute in Biostatistics, *Introduction to Clinical Trials - Days 1* * *and 2* *; Seattle, WA; June 2015.
- Seattle Institute in Biostatistics, *Group Sequential Methods for Clinical Trial Design and Monitoring* *; Seattle, WA; June 2015.
- University of Auckland, *Data Monitoring Committees and Interim Analyses* *; Auckland, NZ; February 2015.
- Seattle Institute in Biostatistics, *Group Sequential Methods for Clinical Trial Design and Monitoring - Days 1 and 2* *; Seattle, WA; August 2014.
- Seattle Institute in Biostatistics, *Introduction to Clinical Trials - Days 1* * *and 2*; Seattle, WA; August 2014.
- Seattle Institute in Biostatistics, *Group Sequential Methods for Clinical Trial Design and Monitoring* *; Seattle, WA; August 2013.
- Seattle Institute in Biostatistics, *Group Sequential Methods for Clinical Trial Design and Monitoring* *; Seattle, WA; August 2012.
- 4th Seattle Symposium on Biostatistics, *Design and Analysis of Group Sequential Trials Using R* *; Seattle, WA; November 2011.
- Summer Institute in Statistical Genetics, University of Washington, *Design, Monitoring, and Analysis of Clinical Trials* *; Seattle, WA; June 2007.
- Insightful Web-Based Training, *Design, Monitoring, and Analysis of Clinical Trials*; April and June 2007.
- Cephalon, *Design, Monitoring, and Analysis of Clinical Trials*; Fraser, PA; November 2006.
- Genentech, *Implementation of Group Sequential Methods Using S+SeqTrial* *; San Francisco, CA; December 2006.
- American Society of Nephrology Annual Conference, *Introduction to Biostatistics* (2000, 2001)
- Department of Nephrology, Puget Sound Healthcare System, *An Introduction to SAS* (2001, 2002)